Keros Therapeutics (NASDAQ: KROS) focuses on rinvatercept and completes $375M capital return

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)

Form Type

DEF 14A

Rhea-AI Filing Summary

Keros Therapeutics calls its 2026 annual meeting for June 3, 2026, asking stockholders to elect two Class III directors, ratify Deloitte & Touche LLP as auditor for 2026, and approve an advisory “say‑on‑pay” vote on executive compensation.

The proxy also describes a major strategic realignment in 2025, with Keros discontinuing material internal development of cibotercept to focus on its lead program, rinvatercept, targeting Duchenne muscular dystrophy and other neuromuscular diseases. The company highlights encouraging Phase 1 data, plans for Phase 2 trials in DMD and ALS, and an ALS collaboration within the Healey ALS MyMatch program.

Keros reports completing a $375 million capital return program through share repurchases, including a tender offer, while indicating it preserved flexibility to fund key clinical priorities. The filing outlines ongoing board refreshment, recent director changes and an independent chair structure, alongside detailed descriptions of board committees, governance practices and stockholder voting mechanics.

Insights

Keros couples a $375M capital return with a focused neuromuscular strategy centered on rinvatercept.

The company reports a strategic pivot in 2025, discontinuing material internal work on cibotercept to concentrate resources on rinvatercept, its lead protein therapeutic. Early Phase 1 data met key safety, tolerability, pharmacokinetic and pharmacodynamic objectives, supporting advancement into Phase 2 for Duchenne muscular dystrophy and exploration of additional neuromuscular indications, including ALS.

At the same time, Keros completed a $375 million capital return program via share repurchases and a tender offer after a review of strategic alternatives. The proxy notes this was intended to deliver immediate value while maintaining flexibility to fund clinical development. The filing also emphasizes board refreshment, an independent chair, and standard proposals: director elections, auditor ratification and an advisory say‑on‑pay vote at the June 3, 2026 virtual meeting.

Key Figures

Capital return program: $375 million Shares outstanding record date: 19,787,837 shares Quorum threshold: 9,893,919 shares +5 more

8 metrics

Capital return program $375 million Authorized by the board and completed via share repurchases and a tender offer

Shares outstanding record date 19,787,837 shares Common stock outstanding and entitled to vote as of April 6, 2026

Quorum threshold 9,893,919 shares Minimum shares required to be present or represented to constitute a quorum

Shares outstanding March 31, 2026 19,732,837 shares Used for beneficial ownership calculations in the security ownership table

2025 audit fees $995,000 Audit fees billed by Deloitte & Touche LLP for the year ended December 31, 2025

Audit research tool fees $1,895 Other fees paid to Deloitte & Touche LLP in each of 2025 and 2024

Proxy solicitor base fee $22,500 Estimated fee payable to MacKenzie Partners, Inc. plus expenses if they assist in soliciting proxies

Board meetings in 2025 22 meetings Total meetings held by the board of directors during fiscal year 2025

Key Terms

Duchenne muscular dystrophy, Phase 2 clinical trial, Healey ALS MyMatch program, say-on-pay, +2 more

6 terms

Duchenne muscular dystrophy medical

"rinvatercept, an asset we believe has therapeutic potential for individuals living with Duchenne muscular dystrophy"

A rare, inherited condition that progressively weakens muscles, Duchenne muscular dystrophy causes the body’s muscle fibers to break down over time, often leading to severe disability. For investors, it matters because the small, well-defined patient population, high unmet medical need and complex regulatory and pricing dynamics mean successes or failures in clinical trials, approvals, or therapies can have outsized effects on a company’s valuation and future revenue prospects.

Phase 2 clinical trial medical

"we are progressing toward commencement of a Phase 2 clinical trial of rinvatercept in patients with DMD"

A phase 2 clinical trial is a research study that tests a new medical treatment or drug to see if it is effective and safe for a specific condition. It involves a larger group of people than earlier trials and helps determine whether the treatment should move forward to more extensive testing. For investors, successful phase 2 results can signal potential for future approval and commercial success, while setbacks may indicate challenges ahead.

Healey ALS MyMatch program medical

"a Phase 2 clinical trial evaluating rinvatercept in patients with ALS within the Healey ALS MyMatch program"

say-on-pay financial

"To approve, on an advisory basis, the compensation of the Company’s named executive officers as disclosed in the proxy statement"

A say-on-pay is a shareholder vote that gives investors a chance to approve or disapprove a company’s executive compensation packages, typically held at annual meetings. It matters because the vote signals investor satisfaction with how leaders are paid—like customers rating how well managers are rewarded—and can push boards to change pay plans, reducing governance risk and affecting investor confidence and stock value even though the vote is usually advisory rather than legally binding.

broker non-votes regulatory

"What are “broker non-votes”? A “broker non-vote” occurs when your broker submits a proxy"

Broker non-votes occur when a brokerage firm is unable to vote on a shareholder’s behalf during a company election or decision because the shareholder has not given specific voting instructions, and the broker is not allowed or chooses not to vote on certain matters. They are important because they can affect the outcome of votes, especially when the results are close, by effectively reducing the total number of votes cast.

plurality voting regulatory

"Directors will be elected by a plurality of the votes cast at the Annual Meeting"

Compensation Summary

Compensation details

Key Proposals

Election of directors
Ratification of independent auditor
Advisory vote on executive compensation

Proxy Statements (DEF 14A): Pay, Votes, and Board Changes →

04/22/2026 - 04:01 PM

TABLE OF CONTENTS

SCHEDULE 14A INFORMATION

Proxy Statement Pursuant to Section 14(a) of the
Securities Exchange Act of 1934
(Amendment No. )

Filed by the Registrant ☒

Filed by a Party other than the Registrant ☐

Check the appropriate box:

☐

Preliminary Proxy Statement

☐

Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))

☒

Definitive Proxy Statement

☐

Definitive Additional Materials

☐

Soliciting Material Pursuant to § 240.14a-12

Keros Therapeutics, Inc.

(Name of Registrant as Specified In Its Charter)

(Name of Person(s) Filing Proxy Statement if Other Than the Registrant)

Payment of Filing Fee (Check the appropriate box):

☒

No fee required.

☐

Fee paid previously with preliminary materials.

☐

Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11.

TABLE OF CONTENTS

April 22, 2026

To our stockholders:

2025 was a year of pivotal change for Keros Therapeutics. We continued to advance our strategy to develop protein therapeutics designed to deliver meaningful, disease-modifying benefits for patients, while maintaining our focus on long-term value creation for our stockholders. Guided by scientific rigor and disciplined execution, we have taken deliberate actions to optimize our performance and position the Company to capitalize on the opportunities ahead, aligning our resources around the development of our key clinical program, rinvatercept (KER-065). As we enter 2026, we are continuing to take steps to reallocate resources and streamline Keros’ operations to create a more efficient structure that best supports patient needs and positions us to deliver on our objectives.

In 2025, we made the strategic decision to exclusively prioritize the clinical advancement of our lead product candidate, rinvatercept, an asset we believe has therapeutic potential for individuals living with Duchenne muscular dystrophy (“DMD”). As part of that initiative, we discontinued all material internal development activities related to cibotercept (KER-012). This decision follows the previously announced termination of the development of cibotercept in pulmonary arterial hypertension (“PAH”), following the analysis of all available safety and efficacy data from the TROPOS Phase 2 clinical trial in patients with PAH. When presented with data that raised potential concerns, we acted promptly and decisively, prioritizing patient safety. These portfolio changes were not easy, but they were deliberate and necessary to sharpen our strategic focus, reinforce disciplined development, and position the Company to advance our highest-priority program while maintaining our commitment to returning capital to stockholders.

We are encouraged by positive data from the Phase 1 clinical trial of rinvatercept, with the trial achieving its key objectives for safety, tolerability, pharmacokinetics and pharmacodynamics. Building on these results, we are progressing toward commencement of a Phase 2 clinical trial of rinvatercept in patients with DMD. We are also evaluating additional neuromuscular indications in which rinvatercept may provide meaningful benefit, including amyotrophic lateral sclerosis (“ALS”). Our initial observations indicate that the observed effect of rinvatercept on skeletal muscle may offer a differentiated approach to treating ALS. In March 2026, we announced that we entered into an agreement with the Massachusetts General Hospital for the design of a Phase 2 clinical trial evaluating rinvatercept in patients with ALS within the Healey ALS MyMatch program, led by the Sean M. Healey & AMG Center for ALS at Mass General Brigham. We expect to engage with regulators in the second half of 2026 to discuss the design of a potential Phase 2 clinical program for ALS. Supported by encouraging early data and disciplined execution, we believe the continued advancement of rinvatercept positions Keros to generate sustainable long-term growth and stockholder value.

As part of our commitment to ongoing Board refreshment and effective governance, we have continued to evolve the composition of our Board in alignment with the Company’s strategic priorities. Over the past five years, three new directors have been added to the Board, broadening its expertise and strengthening its oversight capabilities. Collectively, our directors bring deep experience across the biotechnology and pharmaceutical sectors, including drug discovery, clinical development, regulatory strategy, and commercialization. Their combined scientific, operational, and strategic expertise provides strong guidance to support the Company’s execution and generate sustainable value creation. In March 2026, Charles Newton was appointed to the Keros Board, bringing deep expertise in healthcare finance and capital markets, as well as a strong track record of supporting companies through key value inflection points. We believe his experience and perspective enhance the Board’s capabilities as we advance our clinical and strategic priorities. In conjunction with this appointment, Carl Gordon stepped down from the Board following years of dedicated service. We appreciate his many contributions to Keros and wish him well in his future endeavors.

In line with our strategic realignment efforts and consistent with a disciplined capital allocation framework, we took meaningful steps this year to optimize our capital structure and return excess capital to

TABLE OF CONTENTS

stockholders while allocating the necessary resources to advance our highest-priority programs. Following a comprehensive review of strategic alternatives, our Board authorized a $375 million capital return program that we completed through a combination of share repurchases, including a tender offer that concluded in November 2025. This capital return program enabled us to deliver immediate value to our stockholders while still maintaining financial flexibility to advance our clinical pipeline and position Keros for long-term value creation.

As we move forward in 2026, the Board remains confident in Keros’ ability to deliver on its strategic priorities through focused clinical execution, disciplined capital allocation, and continued progress toward key development milestones.

Thank you for your investment in Keros Therapeutics, continued trust and support.

Sincerely,

Jasbir Seehra, Ph.D.
President and Chief Executive Officer

You are cordially invited to attend the Annual Meeting. Whether or not you expect to attend the Annual Meeting virtually, please vote by telephone or through the internet, or, if you receive a paper proxy card by mail, by completing and returning the proxy card mailed to you, as promptly as possible in order to ensure your representation at the Annual Meeting. Voting instructions are provided in the Notice of Internet Availability of Proxy Materials, or, if you receive a paper proxy card by mail, the instructions are printed on your proxy card and included in the accompanying Proxy Statement. If you participate virtually in the Annual Meeting, you may vote at that time, even if you previously submitted your vote. Please note, however, that if your shares are held of record by a brokerage firm, bank or other agent and you wish to vote at the Annual Meeting, you must obtain a proxy issued in your name from that agent in order to vote your shares that are held in such agent’s name and account.

TABLE OF CONTENTS

KEROS THERAPEUTICS, INC.
1050 Waltham Street, Suite 302
Lexington, Massachusetts 02421

NOTICE OF ANNUAL MEETING OF STOCKHOLDERS

To Be Held On June 3, 2026

To the Stockholders of Keros Therapeutics, Inc.:

NOTICE IS HEREBY GIVEN that the 2026 Annual Meeting of Stockholders (the “Annual Meeting”) of Keros Therapeutics, Inc., a Delaware corporation (the “Company”), will be held on Wednesday, June 3, 2026 at 11:00 a.m. Eastern time in a virtual meeting format only, live via audio webcast for the following purposes:

To elect two (2) nominees for Class III director, Jean-Jacques Bienaimé and Charles Newton, each to hold office until the 2029 Annual Meeting of Stockholders and until their successors are duly elected and qualified.

To ratify the selection by the Audit Committee of the Board of Directors of Deloitte & Touche LLP as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2026.

To approve, on an advisory basis, the compensation of the Company’s named executive officers as disclosed in the proxy statement.

To conduct any other business properly brought before the Annual Meeting.

These items of business are more fully described in the proxy statement accompanying this Notice.

The record date for the Annual Meeting was April 6, 2026 (the “Record Date”). Only stockholders of record at the close of business on the Record Date may vote at the Annual Meeting or any adjournment or postponement thereof.

By Order of the Board of Directors,

Esther Cho
Corporate Secretary

Lexington, Massachusetts
April 22, 2026

TABLE OF CONTENTS

	QUESTIONS AND ANSWERS ABOUT THESE PROXY MATERIALS AND VOTING					1
	PROPOSAL 1 — ELECTION OF DIRECTORS					9
	INFORMATION REGARDING THE BOARD OF DIRECTORS AND CORPORATE GOVERNANCE					12
	INFORMATION REGARDING COMMITTEES OF THE BOARD OF DIRECTORS					15
	PROPOSAL 2 — RATIFICATION OF SELECTION OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM					22
	PROPOSAL 3 — ADVISORY VOTE ON NAMED EXECUTIVE OFFICER COMPENSATION					24
	SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT					25
	EXECUTIVE OFFICERS					27
	EXECUTIVE COMPENSATION					28
	ITEM 402(V) PAY VERSUS PERFORMANCE					51
	NON-EMPLOYEE DIRECTOR COMPENSATION					55
	EQUITY COMPENSATION PLAN INFORMATION					58
	TRANSACTIONS WITH RELATED PERSONS AND INDEMNIFICATION					59
	DELINQUENT SECTION 16(a) REPORTS					62
	HOUSEHOLDING OF PROXY MATERIALS					63
	OTHER MATTERS					64

TABLE OF CONTENTS

KEROS THERAPEUTICS, INC.
1050 Waltham Street, Suite 302
Lexington, Massachusetts 02421

PROXY STATEMENT
FOR THE 2026 ANNUAL MEETING OF STOCKHOLDERS
To Be Held On June 3, 2026

QUESTIONS AND ANSWERS ABOUT THESE PROXY MATERIALS AND VOTING

Who is soliciting my vote?

We are providing you with these proxy materials because the Board of Directors (the “Board”) of Keros Therapeutics, Inc. (the “Company”) is soliciting your proxy to vote at the 2026 Annual Meeting of Stockholders (the “Annual Meeting”) of the Company, including at any adjournments or postponements thereof, to be held on Wednesday, June 3, 2026 at 11:00 a.m. Eastern time in a virtual meeting format only, live via audio webcast.

Do I need to attend the Annual Meeting to vote?

You are invited to attend the Annual Meeting to vote on the proposals described in this proxy statement (the “Proxy Statement”). However, you do not need to attend the Annual Meeting to vote your shares. Instead, you may simply follow the instructions below to submit your proxy over the telephone, through the internet or by mail, and your votes will be cast for you at the Annual Meeting. The proxy materials, including this Proxy Statement and our Annual Report on Form 10-K for the year ended December 31, 2025, are being distributed and made available on or about April 22, 2026. As used in this Proxy Statement, references to “we,” “us,” “our,” “Keros” and the “Company” refer to Keros Therapeutics, Inc. and our consolidated subsidiaries.

Why did I receive a notice regarding the availability of proxy materials on the internet instead of a full set of proxy materials?

Pursuant to rules adopted by the Securities and Exchange Commission (the “SEC”), we have elected to provide access to our proxy materials over the internet rather than printing and mailing the proxy materials. We believe electronic delivery will expedite the receipt of materials and will help lower our costs and reduce the environmental impact of our annual meeting materials. Accordingly, we have sent you a Notice of Internet Availability of Proxy Materials (the “Notice”) because the Board is soliciting your proxy to vote at the Annual Meeting, including at any adjournments or postponements of the meeting.

The Notice will provide instructions as to how you may access and review the proxy materials, including the Notice of Annual Meeting, proxy statement, proxy card and Annual Report on Form 10-K, on the website referred to in the Notice or, alternatively, how to request that a copy of the proxy materials, including a proxy card, be sent to you by mail. The Notice will also provide voting instructions. In addition, stockholders of record may request to receive the proxy materials in printed form by mail or electronically by e-mail on an ongoing basis for future stockholder meetings. Please note that, while our proxy materials are available at the website referenced in the Notice, and our Notice of Annual Meeting, proxy statement and Annual Report on Form 10-K are available on our website, no other information contained on either website is incorporated by reference in or considered to be a part of this document.

We intend to mail the Notice on or about April 22, 2026 to all stockholders of record entitled to vote at the Annual Meeting. The proxy materials, including the Notice, this Proxy Statement and accompanying proxy card or, for shares held in street name (held for your account by a broker or other nominee), voting instruction form, and the Annual Report on Form 10-K for the year ended December 31, 2025 will be made available to stockholders on the internet on the same date.

Will I receive any other proxy materials by mail?

You will not receive any additional proxy materials via mail unless (1) you request a printed copy of the proxy materials in accordance with the instructions set forth in the Notice or (2) we elect, in our discretion,

TABLE OF CONTENTS

to send you a proxy card and a second Notice of Internet Availability of Proxy Materials, which we may send on or after May 2, 2026.

What does it mean if I receive more than one Notice?

If you receive more than one Notice, your shares may be registered in more than one name or in different accounts. Please follow the voting instructions on the Notices to ensure that all of your shares are voted.

How do I attend the Annual Meeting?

To facilitate stockholder participation in the Annual Meeting, the Annual Meeting is being held in a virtual-only format this year. Stockholders attending the virtual Annual Meeting will be afforded the same rights and opportunities to participate as they would at an in-person meeting. The Annual Meeting will be held on Wednesday, June 3, 2026 at 11:00 a.m. Eastern time in a virtual meeting format only. In order to attend the Annual Meeting, you must register at https://web.viewproxy.com/Keros/2026 by 11:59 PM Eastern time on June 2, 2026. On the day of the Annual Meeting, if you have properly registered, you may enter the Annual Meeting by clicking on the link provided via email in your registration confirmations. We encourage you to access the Annual Meeting prior to the start time. Online check-in will begin at 10:45 a.m. Eastern time, and you should allow ample time for the check-in procedures. Both stockholders of record and street name stockholders will need to register to be able to attend the Annual Meeting via live audio webcast, submit their questions during the Annual Meeting and vote their shares electronically at the Annual Meeting by following the instructions below:

If you are a stockholder of record, you must:

•

Follow the instructions provided on your Notice or proxy card to first register at https://web.viewproxy.com/Keros/2026 by 11:59 p.m. Eastern time on June 2, 2026. You will need to enter your name, phone number and email address as part of the registration, following which, you will receive an email confirming your registration, as well as a link to attend the Annual Meeting.

•

On the day of the Annual Meeting, if you have properly registered, you may enter the Annual Meeting by logging in using the link provided via email in your registration confirmation. You will need the virtual control number included on your Notice or proxy card if you chose to vote during the Annual Meeting.

If you hold your shares in street name, you must:

•

Obtain a valid proxy from your broker, bank or other agent if you choose to vote during the Annual Meeting.

•

Register at https://web.viewproxy.com/Keros/2026 by 11:59 p.m. Eastern time on June 2, 2026. You will need to enter your name, phone number and email address, and provide a copy of the legal proxy (which may be uploaded to the registration website or sent via email to VirtualMeeting@viewproxy.com) as part of the registration, following which, you will receive an email confirming your registration, your virtual control number, as well as a link to attend the Annual Meeting. Please note that if you do not provide a copy of the legal proxy, you may still attend the Annual Meeting, but you will be unable to vote your shares electronically at the Annual Meeting.

•

On the day of the Annual Meeting, if you have properly registered, you may enter the Annual Meeting by logging in using the link provided via email in your registration confirmation. You will need the virtual control number assigned to you in your registration confirmation email if you choose to vote during the Annual Meeting.

If you would like to submit a question during the Annual Meeting, you may do so by typing your question in the question/chat section of the Annual Meeting screen. We do not intend to post questions received during the Annual Meeting on our website.

TABLE OF CONTENTS

To help ensure that we have a productive and efficient meeting, and in fairness to all stockholders in attendance, you will also find posted our rules of conduct for the Annual Meeting when you log in prior to its start. These rules of conduct will include the following guidelines:

•

We welcome questions from stockholders. An opportunity will be provided to present questions and comments during the question and answer session, which will include questions submitted live during the Annual Meeting.

•

Only stockholders of record as of the Record Date (as defined below) for the Annual Meeting and their proxy holders may submit questions or comments.

•

You may submit questions electronically through the meeting portal during the Annual Meeting. Live questions will be taken in the order received.

•

Please direct all questions to Jasbir Seehra, Ph.D., our President and Chief Executive Officer.

•

Please include your name and affiliation, if any, when submitting a question or comment.

•

Limit your remarks to one brief question that is relevant to the Annual Meeting and/or our business. Up to one minute will be allocated to read each question.

•

Questions may be grouped by topic by our management.

•

Questions may also be ruled as out of order if they are, among other things, irrelevant to our business, related to pending or threatened litigation, disorderly, repetitious of statements already made, or in furtherance of the speaker’s own personal, political or business interests.

•

Be respectful of your fellow stockholders and Annual Meeting participants.

Further instructions on how to attend the Annual Meeting via live audio webcast, including how to vote your shares electronically at the Annual Meeting, are posted on https://web.viewproxy.com/Keros/2026 under “Frequently Asked Questions.”

What if I have technical difficulties during the check-in time or during the Annual Meeting?

We will have technicians ready to assist you with any technical difficulties you may have accessing the live audio webcast for the Annual Meeting. Please be sure to check in by 10:45 a.m. Eastern time on June 3, 2026, the day of the Annual Meeting, so we may address any technical difficulties before the live audio webcast for the Annual Meeting begins.

If you encounter any difficulties accessing the live audio webcast for the Annual Meeting during the check-in or meeting time, please email VirtualMeeting@viewproxy.com or call 1-866-612-8937.

The platform we are using for the live audio webcast for the Annual Meeting will require the ability to run a temporary application in order for you to join the live audio webcast for the Annual Meeting.

Will a list of record stockholders as of the Record Date be available?

A list of stockholders entitled to vote at the Annual Meeting will be available for examination during normal business hours at our offices by any stockholder of record for any purpose germane to the Annual Meeting for the ten days ending the day prior to the Annual Meeting. Please provide a written request to: Keros Therapeutics, Inc., 1050 Waltham Street, Suite 302, Lexington, Massachusetts 02421, Attention: Corporate Secretary, to arrange for in-person examination.

Who can vote at the Annual Meeting?

Only stockholders at the close of business on April 6, 2026 (the “Record Date”), which we refer to as the stockholders of record, will be entitled to vote at the Annual Meeting. On the Record Date, there were 19,787,837 shares of common stock outstanding and entitled to vote.

Stockholder of Record: Shares Registered in Your Name

If on the Record Date, your shares were registered directly in your name with our transfer agent, Computershare Trust Company, N.A., then you are a stockholder of record. As a stockholder of record,

TABLE OF CONTENTS

you may vote at the Annual Meeting if you participate virtually or vote by proxy. Whether or not you plan to attend the Annual Meeting, we urge you to vote your shares in advance of the Annual Meeting electronically through the internet, over the telephone or by completing and returning a printed proxy card that you may request or that we may elect to deliver at a later time to ensure your vote is counted.

Beneficial Owner: Shares Registered in the Name of a Broker or Bank

If on the Record Date, your shares were held, not in your name, but rather in an account at a brokerage firm, bank or other similar organization, then you are the beneficial owner of shares held in “street name” and the Notice is being forwarded to you by that organization. The organization holding your account is considered to be the stockholder of record for purposes of voting at the Annual Meeting. As a beneficial owner, you have the right to direct your broker, bank or other agent regarding how to vote the shares in your account. You are also invited to attend the Annual Meeting. However, since you are not the stockholder of record, you may not vote your shares at the Annual Meeting even if you participate virtually, unless you request and obtain a valid proxy from your broker, bank or other agent.

What am I voting on?

There are three matters scheduled for a vote:

•

Election of two (2) Class III directors, Jean-Jacques Bienaimé and Charles Newton, each to hold office until the 2029 Annual Meeting of Stockholders (Proposal 1);

•

Ratification of the selection of Deloitte & Touche LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2026 (Proposal 2); and

•

Advisory approval of the compensation of our named executive officers (“NEOs”), as disclosed in this Proxy Statement in accordance with SEC rules (Proposal 3).

What if another matter is properly brought before the Annual Meeting?

The Board knows of no other matters that will be presented for consideration at the Annual Meeting. If any other matters are properly brought before the Annual Meeting, it is the intention of the persons named in the accompanying proxy to vote on those matters in accordance with their best judgment.

How can I vote?

•

With regard to Proposal 1, you may either vote “FOR” all the proposed nominees to the Board or you may “WITHHOLD” your vote for any nominee you specify.

•

With regard to Proposal 2, you may vote “FOR” or “AGAINST” or “ABSTAIN” from voting.

•

With regard to Proposal 3, you may vote “FOR” or “AGAINST” or “ABSTAIN” from voting.

Proxies cannot be voted for a greater number of persons than the two nominees named in this Proxy Statement.

The procedures for voting are fairly simple:

Stockholder of Record: Shares Registered in Your Name

If you are a stockholder of record, you may (1) vote online at the Annual Meeting or (2) in advance of the Annual Meeting, vote by proxy over the telephone, vote by proxy through the internet or vote by proxy using a proxy card that you may request or that we may elect to deliver at a later time. Whether or not you plan to attend the Annual Meeting, we urge you to vote in advance of the Annual Meeting by proxy to ensure your vote is counted. You may still attend the Annual Meeting and vote electronically even if you have already voted by proxy.

•

To vote your shares electronically at the Annual Meeting, you will need to visit www.FCRvote.com/KROS during the Annual Meeting while the polls are open. You will need the virtual control number, which will be included on your Notice or proxy card.

TABLE OF CONTENTS

•

To vote over the telephone, dial toll-free 1-866-402-3905 using a touch-tone phone and follow the recorded instructions. You will be asked to provide the control number from the Notice.

•

To vote through the internet, go to www.FCRvote.com/KROS to complete an electronic proxy card. You will be asked to provide the control number from the Notice.

•

To vote by using a printed proxy card that may be delivered to you, simply complete, sign and date the proxy card and return it promptly in the envelope provided. If you return your signed proxy card to us before the Annual Meeting, we will vote your shares as you direct.

Beneficial Owner: Shares Registered in the Name of Broker or Bank

If you are a beneficial owner of shares registered in the name of your broker, bank or other agent, you should have received a Notice containing voting instructions from that organization rather than from us. Simply follow the voting instructions in the Notice to ensure that your vote is counted. To vote electronically at the Annual Meeting, you must obtain a valid proxy from your broker, bank or other agent. Follow the instructions from your broker, bank or other agent included with these proxy materials, or contact your broker, bank or other agent to request a proxy form. During the Annual Meeting while the polls are open, you will need to visit www.FCRvote.com/KROS to vote electronically. You will need the virtual control number assigned to you in your registration confirmation email.

Internet proxy voting may be provided to allow you to vote your shares online, with procedures designed to ensure the authenticity and correctness of your proxy vote instructions. However, please be aware that you must bear any costs associated with your internet access, such as usage charges from internet access providers and telephone companies.

Can I vote my shares by filling out and returning the Notice?

No. The Notice identifies the items to be voted on at the Annual Meeting, but you cannot vote by marking the Notice and returning it. The Notice provides instructions on how to vote: by telephone, through the internet, by requesting and returning a printed proxy card or by submitting a ballot electronically at the Annual Meeting.

How many votes do I have?

On each matter to be voted upon, you have one vote for each share of common stock you own as of April 6, 2026.

If I am a stockholder of record and I do not vote, or if I return a proxy card or otherwise vote without giving specific voting instructions, what happens?

If you are a stockholder of record and do not vote by telephone, through the internet, by completing the printed proxy card that may be delivered to you or electronically at the Annual Meeting, your shares will not be voted.

If you return a signed and dated proxy card or otherwise vote without marking voting selections, your shares will be voted, as applicable, (1) “FOR” the election of both nominees for director, (2) “FOR” the ratification of Deloitte & Touche LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2026 and (3) “FOR” the advisory approval of our named executive officer compensation. If any other matter is properly presented at the Annual Meeting, your proxyholder (one of the individuals named on your proxy card) will vote your shares using his best judgment.

If I am a beneficial owner of shares held in street name and I do not provide my broker or bank with voting instructions, what happens?

If you are a beneficial owner of shares held in street name and you do not instruct your broker, bank or other agent how to vote your shares, your broker, bank or other agent may still be able to vote your shares in its discretion. Brokers, banks and other securities intermediaries may use their discretion to vote

TABLE OF CONTENTS

your “uninstructed” shares with respect to matters considered to be “routine,” but not with respect to “non-routine” matters. Proposals 1 and 3 are considered to be “non-routine,” meaning that your broker may not vote your shares on those proposals in the absence of your voting instructions. However, Proposal 2 is considered to be a “routine” matter, meaning that if you do not return voting instructions to your broker, bank or other agent by its deadline, your shares may be voted by your broker, bank or other agent in its discretion on Proposal 2.

If you are a beneficial owner of shares held in street name, in order to ensure your shares are voted in the way you would prefer, you must provide voting instructions to your broker, bank or other agent by the deadline provided in the materials you receive from your broker, bank or other agent.

What are “broker non-votes”?

A “broker non-vote” occurs when your broker submits a proxy for the meeting with respect to “routine” matters but does not vote on “non-routine” matters because you did not provide voting instructions on these matters. These unvoted shares with respect to “non-routine” matters are counted as “broker non-votes.” Proposals 1 and 3 are considered to be “non-routine” and we, therefore, expect broker non-votes to exist in connection with those proposals.

As a reminder, if you are a beneficial owner of shares held in street name, in order to ensure your shares are voted in the way you would prefer, you must provide voting instructions to your broker, bank or other agent by the deadline provided in the materials you receive from your broker, bank or other agent.

Can I change my vote after submitting my proxy?

Stockholder of Record: Shares Registered in Your Name

Yes. You can revoke your proxy at any time before the vote during the Annual Meeting. If you are the record holder of your shares, you may revoke your proxy in any one of the following ways:

•

You may grant a subsequent proxy by telephone or through the internet.

•

You may submit another properly completed proxy card with a later date (which automatically revokes the earlier proxy).

•

You may send a timely written notice that you are revoking your earlier-dated proxy to our Corporate Secretary c/o Keros Therapeutics, Inc., 1050 Waltham Street, Suite 302, Lexington, Massachusetts 02421.

•

You may attend the Annual Meeting virtually and vote electronically. Simply attending the Annual Meeting will not, by itself, revoke your proxy. Even if you plan to attend the Annual Meeting, we recommend that you also submit your proxy or voting instructions or vote by telephone or through the internet in advance of the Annual Meeting so that your vote will be counted if you later decide not to attend the Annual Meeting.

Your most current proxy card or telephone or internet proxy is the one that is counted.

Beneficial Owner: Shares Registered in the Name of Broker or Bank

If your shares are held by your broker, bank or other agent, you should follow the instructions provided by your broker, bank or other agent.

How are votes counted?

Votes will be counted by the inspector of election appointed for the Annual Meeting, who will separately count, for:

•

Proposal 1, votes “FOR,” “WITHHOLD” and broker non-votes;

•

Proposal 2, votes “FOR,” “AGAINST” and abstentions; and

•

Proposal 3, votes “FOR,” “AGAINST,” abstentions and, if applicable, broker non-votes.

TABLE OF CONTENTS

Abstentions will be counted towards the vote total for each proposal. Abstentions will have the same effect as “AGAINST” votes on Proposals 2 and 3, and will have no effect on Proposal 1. Broker non-votes on Proposals 1 and 3 will have no effect and will not be counted towards the vote total for any of those proposals.

How many votes are needed to approve each proposal?

The following table summarizes the minimum vote needed to approve each proposal and the effect of abstentions and broker non-votes.

Proposal
No.

Proposal Description

Vote Required for Approval

Effect of
Abstentions

Effect of
Broker
Non-Votes

Election of directors

Directors will be elected by a plurality of the votes cast at the Annual Meeting by the holders of shares present by remote communication or represented by proxy and entitled to vote on the election of directors. The two nominees receiving the most “FOR” votes will be elected as directors; withheld votes will have no effect

Under plurality voting, there are no abstentions

No effect

Ratification of the selection of Deloitte & Touche LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2026

“FOR” votes from the holders of a majority of shares present by remote communication or represented by proxy and entitled to vote on the subject matter

Against

Not applicable(1)

Advisory approval of the compensation of our named executive officers

“FOR” votes from the holders of a majority of shares present by remote communication or represented by proxy and entitled to vote on the subject matter

Against

No effect

(1)

This proposal is considered to be a “routine” matter. Accordingly, if you hold your shares in street name and do not provide voting instructions to your broker, bank or other agent that holds your shares, your broker, bank or other agent has discretionary authority to vote your shares on this proposal.

What is the quorum requirement?

A quorum of stockholders is necessary to hold a valid meeting. A quorum will be present if stockholders holding at least a majority of the outstanding shares entitled to vote at the Annual Meeting are present virtually at the Annual Meeting or represented by proxy. On the Record Date, there were 19,787,837 shares outstanding and entitled to vote. Thus, the holders of 9,893,919 shares must be present virtually or represented by proxy at the Annual Meeting to have a quorum.

Your shares will be counted towards the quorum only if you submit a valid proxy (or one is submitted on your behalf by your broker, bank or other nominee) or if you vote electronically at the Annual Meeting. Abstentions and broker non-votes will be counted towards the quorum requirement. If there is no quorum, the holders of a majority of shares present at the meeting virtually or represented by proxy may adjourn the meeting to another date.

TABLE OF CONTENTS

How can I find out the results of the voting at the Annual Meeting?

Preliminary voting results will be announced at the Annual Meeting. In addition, final voting results will be published in a current report on Form 8-K that we expect to file within four business days after the Annual Meeting. If final voting results are not available to us in time to file a Form 8-K within four business days after the Annual Meeting, we intend to file a Form 8-K to publish preliminary results and, within four business days after the final results are known to us, file an additional Form 8-K to publish the final results.

Who is paying for this proxy solicitation?

We will pay for the entire cost of soliciting proxies. In addition to these proxy materials, our directors and employees may also solicit proxies in person, by telephone or by other means of remote communication. Directors and employees will not be paid any additional compensation for soliciting proxies. We engaged MacKenzie Partners, Inc. to assist us with our stockholder engagement process, and we may pay them an estimated fee of $22,500 plus reasonable out-of-pocket expenses if they assist us in soliciting proxies. In addition, we have agreed to indemnify MacKenzie Partners, Inc. and certain related persons against certain liabilities relating to or arising out of MacKenzie Partners, Inc.’s engagement. We may also reimburse brokerage firms, banks and other agents for the cost of forwarding proxy materials to beneficial owners.

When are stockholder proposals and director nominations due for next year’s annual meeting?

To be considered for inclusion in next year’s proxy materials, you must submit your proposal, in writing, by December 23, 2026, to our Corporate Secretary c/o Keros Therapeutics, Inc., 1050 Waltham Street, Suite 302, Lexington, Massachusetts 02421, and you must comply with all applicable requirements of Rule 14a-8 promulgated under the Securities Exchange Act of 1934, as amended (the “Exchange Act”). Nothing in this paragraph shall require us to include in our proxy statement or proxy card for the 2027 Annual Meeting any stockholder proposal that does not meet the requirements of the SEC in effect at the time.

Our bylaws also establish an advance notice procedure if you wish to present a proposal before an annual meeting of stockholders but you are not requesting that your proposal or nomination be included in next year’s proxy materials. To be timely for our 2027 Annual Meeting of Stockholders, our Corporate Secretary must receive the written notice at our principal executive offices not later than the close of business on March 5, 2027 nor earlier than the close of business on February 3, 2027. However, if we hold our 2027 Annual Meeting of Stockholders more than 30 days before or after June 3, 2027 (the one-year anniversary date of the 2026 Annual Meeting of Stockholders), then timely notice of a stockholder proposal that is not intended to be included in our proxy statement must be received not earlier than the close of business on the 120th day prior to the 2027 Annual Meeting of Stockholders and not later than the close of business on the later of the 90th day prior to the 2027 Annual Meeting of Stockholders or the 10th day following the day on which public announcement of the date of the 2027 Annual Meeting of Stockholders is first made. You are also advised to review our bylaws, which contain additional requirements about advance notice of stockholder proposals and director nominations. In addition, stockholders who intend to solicit proxies in support of director nominees other than the Company’s nominees must also comply with the additional requirements of Rule 14a-19(b) of the Exchange Act.

TABLE OF CONTENTS

PROPOSAL 1
ELECTION OF DIRECTORS

Our Board is divided into three classes. Each class consists, as nearly as possible, of an equal number of directors, and each class has a three-year term. Vacancies on the Board may be filled only by persons elected by a majority of the remaining directors. A director elected by the Board to fill a vacancy in a class, including vacancies created by an increase in the number of directors, shall serve for the remainder of the full term of that class and until the director’s successor is duly elected and qualified.

The Board presently has seven members. There are two Class III directors whose terms of office expire in 2026: Jean-Jacques Bienaimé and Charles Newton. Mr. Bienaimé and Mr. Newton, both current directors, have been nominated for reelection at the Annual Meeting by the Board. If elected at the Annual Meeting, each of these nominees would serve until the 2029 Annual Meeting of Stockholders and until his successor has been duly elected and qualified, or, if sooner, until his death, resignation or removal. It is our policy to invite directors and nominees for director to attend the Annual Meeting.

Vote Required

Directors are elected by a plurality of the votes of the holders of shares present by virtual attendance or represented by proxy and entitled to vote on the election of directors. Accordingly, if a quorum is present, the two nominees receiving the highest number of affirmative votes will be elected as Class III directors. Shares represented by executed proxies will be voted, if authority to do so is not withheld, for the election of the nominees named below. Proxies cannot be voted for a greater number of persons than the two nominees named in this Proxy Statement. If any nominee becomes unavailable for election as a result of an unexpected occurrence, shares that would have been voted for that nominee will instead be voted for the election of a substitute nominee that we will propose. Each nominee has agreed to serve if elected. Our management has no reason to believe that any nominee will be unable to serve.

Director Nominees and Continuing Directors

The Board and the Nominating and Corporate Governance Committee seek to assemble a Board that, as a whole, possesses the appropriate balance of professional and industry knowledge, financial expertise, backgrounds and high-level management experience necessary to oversee and direct our business. To that end, the Board has identified and evaluated nominees in the broader context of the Board’s overall composition, with the goal of recruiting members who complement and strengthen the skills of other members and who also exhibit integrity, collegiality, sound business judgment and other qualities that the Board and the Nominating and Corporate Governance Committee view as critical to effective functioning of the Board.

The following is a brief biography of each nominee for director and each director whose term of office will continue after the Annual Meeting, and a discussion of the specific experience, qualifications, attributes or skills of each nominee that led the Board to recommend that person as a nominee for director, as of the date of this Proxy Statement. However, each of the members of the Board may have a variety of reasons why a particular person would be an appropriate nominee for the Board, and these views may differ from the views of other members.

Nominees for Election as a Class III Director for a Three-Year Term Expiring at the 2029 Annual Meeting of Stockholders

Jean-Jacques Bienaimé, age 72, has served as a member of our Board since June 2024, served as Lead Independent Director of our Board from July 2024 to August 2025, and has served as Chair of our Board since August 2025. Mr. Bienaimé served as the Chief Executive Officer of BioMarin Pharmaceutical Inc. from May 2005, and as the Chairman from June 2015, until his retirement from BioMarin in December 2023. From November 2002 to April 2005, Mr. Bienaimé served as the Chairman, Chief Executive Officer and President of Genencor, Inc., a biotechnology company focused on industrial bioproducts and targeted cancer biotherapeutics. Prior to Genencor, Mr. Bienaimé served as Chairman, Chief Executive Officer and President of Sangstat Medical Corporation, an immunology-focused biotechnology company, from 1998 to late 2002, becoming President in 1998 and Chief Executive Officer in 1999. Mr. Bienaimé also held several senior management positions at Rhône-Poulenc Rorer Pharmaceuticals (now Sanofi-Aventis) from 1992 to

TABLE OF CONTENTS

1998, culminating in the position of Senior Vice President of Worldwide Marketing and Business Development. Earlier in his career, Mr. Bienaimé worked at Genentech, Inc. where he was involved in the launch of tissue plasminogen activator (t-PA) for the treatment of heart attacks. Mr. Bienaimé currently serves on the board of directors of Ascendis Pharma A/S, Incyte Corporation and Immunome, Inc., as well as serving on the board of directors of two private biotechnology companies. Mr. Bienaimé received an M.B.A. from the Wharton School at the University of Pennsylvania and a degree in economics from the École Supérieure de Commerce de Paris. Our Board believes that Mr. Bienaimé’s extensive business experience in the life science and biotechnology sectors, including experience managing and serving on boards of public biotechnology companies, qualify him to serve on our Board.

Charles Newton, age 55, has served as a member of our Board since March 2026. Mr. Newton served as the Chief Financial Officer of Lyell Immunopharma, Inc. from February 2021 until his retirement from Lyell in October 2025. From November 2015 to February 2021, he served as Managing Director & Co-Head of Healthcare Investment Banking in the Americas at Bank of America Merrill Lynch. From September 2010 to November 2015, Mr. Newton served as Managing Director at Credit Suisse where his last position was Co-Head of Healthcare Investment Banking in the Americas. From June 1996 to September 2010, he served in the investment banking division at Morgan Stanley where his last position was Managing Director and Head of Western Region Healthcare Investment Banking. Earlier in his career, Mr. Newton served as an Investment Banking Analyst at Lehman Brothers and as a Financial Analyst at Mercer Global Advisors. Mr. Newton currently serves as a member of the board of directors of Coherus Oncology, Inc. and Novavax Inc. He previously served as a member of the board of directors of 2seventy bio, Inc., until its acquisition by Bristol-Myers Squibb, and Carmot Therapeutics, until its acquisition by Roche. Mr. Newton received an M.B.A. from The Tuck School at Dartmouth College and a B.S. in Finance from Miami University. Our Board believes that Mr. Newton’s extensive management and financial experience in the life science and biotechnology sectors qualify him to serve on our Board.

THE BOARD OF DIRECTORS UNANIMOUSLY RECOMMENDS A VOTE “FOR” EACH
CLASS III DIRECTOR NOMINEE NAMED ABOVE.

Class I Directors Continuing in Office Until the 2027 Annual Meeting of Stockholders

Jasbir Seehra, Ph.D., age 70, has served as our Co-Founder, Chief Executive Officer and as a member of our Board since December 2015. He previously served as Chair of our Board from July 2024 to August 2025. Prior to joining us, Dr. Seehra served as the Chief Scientific Officer at Ember Therapeutics, Inc. from December 2011 to April 2015. From February 2004 to November 2010, Dr. Seehra served as the Co-Founder and Chief Scientific Officer of Acceleron Pharma Inc. He has also served as Vice President of Biological Chemistry at Wyeth Pharmaceuticals Inc. and led the small molecule lead discovery effort at Genetics Institute, Inc., where he helped build the institute’s small molecule drug discovery capabilities, including medicinal chemistry, high throughput screening and structural biology. Dr. Seehra previously served on the board of directors of Eloxx Pharmaceuticals, Inc. and on the board of a private life science company. Dr. Seehra received a B.Sc. and a Ph.D. in Biochemistry from the University of Southampton in England. He completed his postdoctoral work at the Massachusetts Institute of Technology. Our Board believes that Dr. Seehra’s extensive experience in the pharmaceutical industry and executive leadership experience provides him with the qualifications to serve on our Board.

Nima Farzan, age 50, has served as a member of our Board since March 2020. Mr. Farzan has served as the Chief Executive Officer at Latigo Biotherapeutics since July 2024. He served as a Venture Partner at Foresite Capital from April 2024 to July 2024. Previously, he served as the Chief Executive Officer and director of Kinnate Biopharma Inc. from March 2020 until the company’s acquisition by XOMA Corporation in April 2024. Mr. Farzan served as an advisor for a number of life sciences companies from October 2018 to February 2020. From 2011 to October 2018, Mr. Farzan was employed by PaxVax Corporation, serving as its President and Chief Executive Officer from April 2015 until the company’s acquisition by Emergent Biosolutions Inc. in October 2018. Prior to PaxVax, Mr. Farzan held positions of increasing seniority at Novartis AG from 2003 to 2011. From 1999 to 2002, Mr. Farzan served in various marketing and business development positions at DoubleTwist, Inc. and from 1997 to 1999, Mr. Farzan served as an associate at The Boston Consulting Group. Mr. Farzan has a bachelor’s degree in Human Biology from Stanford University and an M.B.A. from the Harvard Business School. Our Board believes that Mr. Farzan’s significant industry experience and corporate management experience qualify him to serve on our Board.

TABLE OF CONTENTS

Julius Knowles, age 63, has served as a member of our Board since April 2016. Since January 2014, Mr. Knowles has served as a Partner at Mass General Brigham Ventures (formerly known as Partners Innovation Fund), the venture arm of Mass General Brigham (formerly known as Partners HealthCare). From March 2012 to January 2014, Mr. Knowles served as the Chief Executive Officer of X-BODY BioSciences Inc. (acquired by Juno Therapeutics, Inc.). From October 2006 to February 2012, Mr. Knowles was responsible for global technology and drug discovery collaborations at Novartis, including as the Head of the Platforms team for Strategic Alliances at Novartis Institute of Biomedical Research. From March 2002 to June 2006, Mr. Knowles served as the President of Novalar Pharmaceuticals, Inc. Mr. Knowles previously served as the Vice President of Business Development of Novacea, Inc. from June 2001 to March 2002, the Vice President of Business Development of SGX Pharmaceuticals, Inc. from October 1999 to June 2001 and the Director of Research and Development Planning at Vertex Pharmaceuticals, Inc. from June 1993 to October 1999. Mr. Knowles also serves on the board of several private life science companies. Mr. Knowles received a B.A. with distinction in Chemistry from Carleton College, an M.B.A. from the Wharton School at University of Pennsylvania and an M.Sc. in Chemistry from UC Berkeley. Our Board believes Mr. Knowles’ significant industry experience and corporate management experience qualify him to serve on our Board.

Class II Directors Continuing in Office Until the 2028 Annual Meeting of Stockholders

Mary Ann Gray, Ph.D., age 73, has served as a member of our Board since December 2020. Dr. Gray has been President of Gray Strategic Advisors, LLC, a biotechnology strategic planning and advisory firm, since September 2003. Previously, she served as Senior Analyst and Portfolio Manager of Federated Kaufmann Fund. Prior to Federated, she served as a biotechnology equity research analyst at multiple firms. Earlier in her career, she worked as a senior scientist both at Schering Plough Research and NeoRx Corporation. Dr. Gray currently serves on the board of directors of BioAtla, Inc. and Compass Therapeutics Inc. and previously served on the board of directors of many public and private biotechnology companies. Dr. Gray earned a B.S. from University of South Carolina, a Ph.D. in Pharmacology from the University of Vermont and completed her post-doctoral work at Northwestern University Medical School and at the Yale University School of Medicine. Our Board believes that Dr. Gray’s extensive experience in the biotechnology and biopharmaceutical industry qualifies her to serve on our Board.

Alpna Seth, Ph.D., age 62, has served as a member of our Board since May 2023. Dr. Seth retired in October 2022 as the President and Chief Executive Officer of Nura Bio Inc., where she served for three years. From July 2017 to January 2019, Dr. Seth was the Chief Operating Officer of Vir Biotechnology, Inc. Prior to joining Vir, Dr. Seth served in several senior global leadership roles of increasing responsibility at Biogen Inc. Most recently, she was Senior Vice President and Global Head of the Biosimilars Business Unit at Biogen Inc. for which she relocated to Europe in 2014. From 1998 through July 2017, Dr. Seth held a range of general management roles at Biogen spanning drug development, commercialization, and international operations, including founding Managing Director of Biogen Idec India and Program Executive for several of Biogen’s major cross-functional drug development programs and commercial product launches. Dr. Seth currently serves on the board of directors of Bio-Techne Corporation and Dr. Reddy’s Laboratories. Dr. Seth previously served on the board of directors of Seagen Inc. from 2018 until the company’s acquisition by Pfizer Inc. in December 2023. Dr. Seth received a Ph.D. in Biochemistry and Molecular Biology from University of Massachusetts Medical School and conducted her post-doctoral research at Harvard University in Immunology and Structural Biology, both as a Howard Hughes Medical Institute Fellow. She is also a graduate of the Advanced Management Program at Harvard Business School. Our Board believes that Dr. Seth’s extensive experience in the life sciences industry as well as her corporate management experience qualifies her to serve on our Board.

TABLE OF CONTENTS

INFORMATION REGARDING THE BOARD OF DIRECTORS AND
CORPORATE GOVERNANCE

Board Demographics

The directors’ demographic backgrounds include gender (two directors) and racial/ethnic diversity (three directors) based on self-identification.

Independence of The Board of Directors

As required under Nasdaq listing standards, a majority of the members of a listed company’s board of directors must qualify as “independent,” as affirmatively determined by the company’s board. The Board consults with the Company’s counsel to ensure that the Board’s determinations are consistent with relevant securities and other laws and regulations regarding the definition of “independent,” including those set forth in pertinent listing standards of Nasdaq, as in effect from time to time.

Consistent with these considerations, after review of all relevant identified transactions or relationships between each director, or any of his or her family members, and the Company, our senior management and our independent registered public accounting firm, the Board has affirmatively determined that the following six directors are independent directors within the meaning of the applicable Nasdaq listing standards: Mr. Bienaimé, Mr. Farzan, Dr. Gray, Mr. Knowles, Mr. Newton and Dr. Seth. In making this determination, the Board found that none of these directors or nominees for director had a material or other disqualifying relationship with us. Dr. Seehra is not an independent director by virtue of his employment with us.

Accordingly, a majority of our directors are independent, as required under applicable Nasdaq rules. In making this determination, our Board considered the applicable Nasdaq rules and the current and prior relationships that each non-employee director has with us and all other facts and circumstances our Board deemed relevant in determining their independence, including their beneficial ownership of our capital stock.

Corporate Governance Highlights

•

Annual ‘Say-on-Pay’ vote

•

Independent Chair with a robust set of responsibilities

•

Regular executive Board sessions, without management present

•

Annual Board and committee self-evaluations

•

Active stockholder engagement program

•

Board oversight of key risks related to our Company, including cybersecurity, human capital management and succession planning

Board Leadership Structure

The Board believes that it is important to retain the flexibility to allocate the responsibilities of the offices of the Chair of the Board and Chief Executive Officer in any manner that it determines to be in the best interests of the Company and execution of our strategy at that time. Accordingly, our Corporate Governance Guidelines specifically maintains the flexibility to determine whether the roles of Chair and Chief Executive Officer should be combined or separated. The Board reviews its leadership structure periodically as part of its annual self-assessment process. In addition, the Board continues to monitor developments in corporate governance as well as the approaches our peers undertake.

To better align the operational leadership of the Company, in July 2024, the Board determined that combining the Chair and Chief Executive Officer positions under the leadership of Dr. Seehra would be in the best interests of the Company and our stockholders. This determination was based on the Board’s strong belief that, as the individual with primary responsibility for managing the Company’s day-to-day operations and with extensive knowledge and understanding of the Company, combining the roles of Chair and

TABLE OF CONTENTS

Chief Executive Officer in Dr. Seehra creates a clear line of authority that promotes decisive and effective leadership, both within and outside the Company. In making this judgment, the Board took into account its evaluation of Dr. Seehra’s performance as Chief Executive Officer and as a current member of the Board, his rapport with the other directors, his vast expertise in the pharmaceutical industry, and the strategic perspective he would bring to the role of Chair.

In August 2025, the Company announced a strategic realignment designed to reallocate resources towards the development of its key clinical program, rinvatercept. To support this strategic realignment, Dr. Seehra assumed the additional role of President and stepped down as Chair, continuing as a director of the Board. In his capacity as President and Chief Executive Officer, Dr. Seehra continues to oversee the execution of our strategy and is deeply engaged in the day-to-day operations and scientific advancement of our pipeline. Mr. Bienaimé assumed the role of Chair effective on Dr. Seehra stepping down as Chair in August 2025. The Chair is responsible for:

•

calling meetings of the Board;

•

presiding at meetings of the Board and at meetings of the stockholders;

•

approving Board meeting schedules and meeting agendas; and

•

approving Board meeting materials.

The Board recognizes the importance of separating the positions of Chair and Chief Executive Officer, given the added responsibilities given to Dr. Seehra as President of the Company. This separation reinforces the independence of the Board in its oversight of our business and affairs. In addition, we believe that having an independent Chair creates an environment that is more conducive to objective evaluation and oversight of management’s performance, increasing management accountability and improving the ability of the Board to monitor whether management’s actions are in the best interests of the Company and our stockholders. As a result, we believe that having an independent Chair can enhance the effectiveness of the Board as a whole. We believe that the leadership structure of our Board is appropriate and enhances its ability to effectively carry out its roles and responsibilities on behalf of our stockholders.

Role of the Board in Risk Oversight

The Company is subject to a variety of risks, including those described under the section entitled “Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2025. Some risks may be readily perceived and even quantified, while others are unexpected or unforeseeable. Risks can be external or can arise as a result of our internal business or financial activities.

The Board and our executive management team work together to manage our risks. It is management’s responsibility to identify various risks facing the Company, bring the Board’s attention to material risks, and implement appropriate risk management policies and procedures to manage risk exposure on a day-to-day basis. The Board has an active role in overseeing our risk management process directly or through its committees. The Board does not have a standing risk management committee, but rather administers this oversight function directly through the Board as a whole, as well as through various Board standing committees that address risks inherent in their respective areas of oversight. The full Board has oversight and has been engaged concerning the monitoring and identification of risks to the Company. Risk assessment reports are periodically provided by management to the Board, and management regularly provides updates to the Board related to legal and compliance risks and cybersecurity initiatives, including our ability to respond to any cyber-attacks.

The Board has delegated responsibility for the oversight of specific risks to the Board committees as follows:

•

Our Audit Committee oversees management of financial, accounting, operational, tax, privacy and cybersecurity and information technology risks. In addition to fulfilling its responsibilities for the oversight of our financial reporting processes and annual audit of the Company’s financial statements, our Audit Committee also reviews with the Company’s independent registered public accounting firm and the Company’s management the adequacy and effectiveness of our policies and procedures to assess, monitor and manage fraud risk and our ethical compliance program. The

TABLE OF CONTENTS

Audit Committee is also responsible for reviewing with management and our auditors, as appropriate, our major financial risk exposures and the steps taken by management to monitor and control these exposures, and material risks relating to data privacy, technology and information security, including cybersecurity, threats and back-up of information systems. Our Audit Committee takes appropriate actions to set the best practices and highest standards for quality financial reporting, sound business risk practices and ethical behavior.

•

Our Compensation Committee is responsible for overseeing the management of risks relating to our compensation policies and practices for all employees, including non-executive officers. In connection with structuring the executive compensation program, our Compensation Committee, together with the Board, considers whether the elements of such program, individually or in the aggregate, encourage our executive management team to take unnecessary risks.

•

Our Nominating and Corporate Governance Committee manages the Company’s corporate governance practices and monitors the effectiveness of our Corporate Governance Guidelines, including whether they are successful in preventing illegal or improper liability-creating conduct. Our Nominating and Corporate Governance Committee also reviews risks associated with the independence of the Board, potential conflicts of interest and risks relating to management and Board succession planning.

It is the responsibility of the chairperson of each committee of the Board to report findings regarding material risk exposures to the Board as quickly as possible. The Board has delegated to the Board Chair the responsibility of coordinating between the Board and management with regard to the determination and implementation of responses to any problematic risk management issues.

Meetings of the Board of Directors and Attendance

The Board met 22 times during 2025. Each Board member attended 75% or more of the aggregate number of meetings of the Board and of the committees on which he or she served held during the portion of the last fiscal year for which he or she was a director or committee member. It is our policy to encourage our directors to attend the Annual Meeting. All of our directors attended our 2025 annual meeting of stockholders.

TABLE OF CONTENTS

INFORMATION REGARDING COMMITTEES OF THE BOARD OF DIRECTORS

The Board has three committees: an Audit Committee, a Compensation Committee and a Nominating and Corporate Governance Committee. The following table provides membership and meeting information for the 2025 fiscal year for each of the Board committees:

Name

Audit

Compensation

Nominating and
Corporate
Governance

Jean-Jacques Bienaimé

X*(1)

Nima Farzan

Carl L. Gordon, Ph.D., C.F.A.(2)

Mary Ann Gray, Ph.D.†

Tomer Kariv(3)

X*(3)

Julius Knowles

Ran Nussbaum(4)

Alpna Seth, Ph.D.

Total meetings in fiscal 2025

Committee Chairperson

†

Financial Expert

(1)

Mr. Bienaimé was appointed to serve as the Chair of the Nominating and Corporate Governance Committee in October 2025, prior to which he served as a member of the Nominating and Corporate Governance Committee.

(2)

Dr. Gordon resigned from our Board and all committees thereof in March 2026.

(3)

Mr. Kariv resigned from our Board and all committees thereof in October 2025.

(4)

Mr. Nussbaum resigned from our Board and all committees thereof in October 2025.

Below is a description of each committee of the Board.

Each of the committees has authority to engage legal counsel or other experts or consultants, as it deems appropriate to carry out its responsibilities. The Board has determined that each member of each committee meets the applicable Nasdaq rules and regulations regarding “independence,” and each member is free of any relationship that would impair his or her individual exercise of independent judgment with regard to the Company.

Audit Committee

The Audit Committee is currently composed of four directors: Dr. Gray (Chair), Mr. Farzan, Mr. Knowles and Mr. Newton. The Audit Committee met four times during 2025. The Audit Committee also acts periodically by unanimous written consent in lieu of a formal meeting. The Board has adopted a written Audit Committee charter that is available to stockholders on our website at ir.kerostx.com.

The Board reviews the Nasdaq listing standards definition of independence for Audit Committee members on an annual basis and has determined that all of the current members of the Audit Committee are independent (as independence is currently defined under Rule 5605(c)(2)(A)(i) and (ii) of the Nasdaq listing rules and under Rule 10A-3 under the Exchange Act). The Board has also determined that each of Dr. Gray and Mr. Newton qualifies as an “audit committee financial expert,” as defined in applicable SEC rules. The Board made a qualitative assessment of Dr. Gray’s and Mr. Newton’s respective levels of knowledge and experience based on a number of factors, including her and his formal education and previous and current experience serving on the audit committee of other public companies.

The Audit Committee was established by the Board in accordance with Section 3(a)(58)(A) of the Exchange Act to oversee our corporate accounting and financial reporting processes and audits of its

TABLE OF CONTENTS

financial statements. For this purpose, the Audit Committee performs several functions. The principal duties and responsibilities of the Audit Committee include, among other things:

•

evaluating the performance, independence and qualifications of our independent auditors and determining whether to retain our existing independent auditors or engage new independent auditors;

•

reviewing and approving the engagement of our independent auditors to perform audit services and any permissible non-audit services;

•

monitoring the rotation of partners of our independent auditors on our engagement team as required by law;

•

prior to engagement of any independent auditor, and at least annually thereafter, reviewing relationships that may reasonably be thought to bear on their independence, and assessing and otherwise taking the appropriate action to oversee the independence of our independent auditor;

•

reviewing our annual and quarterly financial statements and reports, including the disclosures contained under the caption “Management’s Discussion and Analysis of Financial Condition and Results of Operations,” and discussing the statements and reports with our independent auditors and management;

•

reviewing with our independent auditors and management significant issues that arise regarding accounting principles and financial statement presentation and matters concerning the scope, adequacy and effectiveness of our financial controls;

•

reviewing with management and our auditors any earnings announcements;

•

establishing procedures for the receipt, retention and treatment of complaints received by us regarding financial controls, accounting or auditing matters and other matters;

•

preparing the report that the SEC requires in our annual proxy statement;

•

reviewing and providing oversight of any related-person transactions in accordance with our related person transaction policy and reviewing and monitoring compliance with legal and regulatory responsibilities, including our Code of Business Conduct and Ethics;

•

reviewing our major financial risk exposures, including the guidelines and policies to govern the process by which risk assessment and risk management is implemented;

•

reviewing and discussing with our Head of Information Technology material risks relating to data privacy, technology and information security, including cybersecurity, threats and back-up of information systems and our processes for assessing, identifying, and managing such risks; and

•

reviewing and evaluating on an annual basis the performance of the Audit Committee and the Audit Committee charter.

Report of the Audit Committee of the Board of Directors

The Audit Committee has reviewed and discussed the audited financial statements for the fiscal year ended December 31, 2025 with our management. The Audit Committee has also reviewed and discussed with Deloitte & Touche LLP, our independent registered public accounting firm, the matters required to be discussed by the applicable requirements of the Public Company Accounting Oversight Board (“PCAOB”) and the SEC. The Audit Committee has also received the written disclosures and the letter from Deloitte & Touche LLP required by applicable requirements of the PCAOB regarding the independent accountants’ communications with the Audit Committee concerning independence, and has discussed with Deloitte & Touche LLP the accounting firm’s independence. Based on the foregoing, the Audit Committee has recommended to the Board that the audited financial statements be included in our Annual Report on Form 10-K for the year ended December 31, 2025 and filed with the SEC.

Members of the Audit Committee

Mary Ann Gray, Chair
Nima Farzan
Julius Knowles
Charles Newton

TABLE OF CONTENTS

The material in this report is not “soliciting material,” is not deemed “filed” with the SEC and is not to be incorporated by reference in any filing of the Company under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date hereof and irrespective of any general incorporation language in any such filing.

Compensation Committee

The Compensation Committee is currently composed of four directors: Dr. Seth (Chair), Mr. Farzan, Dr. Gray and Mr. Newton. All members of our Compensation Committee are independent (as independence is currently defined in Rule 5605(d)(2) of the Nasdaq listing rules). The Compensation Committee met six times during 2025. The Board has adopted a written Compensation Committee charter that is available to stockholders on our website at ir.kerostx.com.

The Compensation Committee acts on behalf of the Board to review, adopt and approve the Company’s compensation strategy, policies, plans and programs, including:

•

overseeing our overall compensation practices and objectives, and assessing whether our compensation practices establish appropriate incentives in light of our specific business objectives;

•

reviewing and approving (or if it deems appropriate, making recommendations to the full Board regarding) the compensation and other terms of employment of our executive officers;

•

reviewing and approving (or if it deems appropriate, making recommendations to the full Board regarding) performance goals and objectives relevant to the compensation of our executive officers and assessing their performance against these goals and objectives;

•

reviewing and approving (or if it deems it appropriate, making recommendations to the full Board regarding) the equity incentive plans, compensation plans and similar programs advisable for us, as well as modifying or terminating existing plans and programs;

•

evaluating risks associated with our compensation policies and practices and assessing whether risks arising from our compensation policies and practices for our employees are reasonably likely to have a material adverse effect on us;

•

reviewing and making recommendations to the full Board regarding the type and amount of compensation to be paid or awarded to our non-employee Board members;

•

reviewing and assessing the independence of compensation consultants, legal counsel and other advisors as required by Section 10C of the Exchange Act;

•

administering our equity compensation plans, pension and profit-sharing plans, stock purchase plans, bonus plans, deferred compensation plans and other similar plans and programs;

•

providing recommendations to the Board on compensation-related proposals to be considered at the Company’s annual meeting of stockholders, including reviewing and considering the results of any advisory vote on NEO compensation;

•

establishing, approving, modifying and overseeing our compensation clawback or similar policies, including a clawback policy that complies with the requirements of the SEC and the Nasdaq listing standards, and any required recoupment and disclosure;

•

reviewing and discussing with management our policies and practices related to our management of human capital resources, including talent development, retention, overall employee wellness and engagement of Company personnel;

•

preparing the report that the SEC requires in our annual proxy statement; and

•

reviewing and evaluating on an annual basis the performance of the Compensation Committee and the Compensation Committee charter.

Compensation Committee Processes and Procedures

Typically, the Compensation Committee meets quarterly and with greater frequency if necessary. The Compensation Committee also acts periodically by unanimous written consent in lieu of a formal meeting.

TABLE OF CONTENTS

The agenda for each meeting is usually developed by the Chair of the Compensation Committee, in consultation with management. The Compensation Committee meets regularly in executive session. However, from time to time, various members of management and other employees as well as outside advisers or consultants may be invited by the Compensation Committee to make presentations, to provide financial or other background information or advice or to otherwise participate in Compensation Committee meetings. Our Chief Executive Officer may not participate in, or be present during, any deliberations or determinations of the Compensation Committee regarding his compensation or individual performance objectives.

The charter of the Compensation Committee grants the Compensation Committee full access to all books, records, facilities and personnel of the Company. In addition, under the charter, the Compensation Committee has the authority to obtain, at our expense, advice and assistance from compensation consultants and internal and external legal, accounting or other advisers and other external resources that the Compensation Committee considers necessary or appropriate in the performance of its duties. The Compensation Committee has direct responsibility for the oversight of the work of any consultants or advisers engaged for the purpose of advising the Compensation Committee. In particular, the Compensation Committee has the sole authority to retain, in its sole discretion, compensation consultants to assist in its evaluation of executive and director compensation, including the authority to approve the consultant’s reasonable fees and other retention terms. Under its charter, the Compensation Committee may select, or receive advice from, a compensation consultant, legal counsel or other adviser to the Compensation Committee, other than in-house legal counsel and certain other types of advisers, only after assessing the independence of such person in accordance with SEC and Nasdaq requirements that bear upon the adviser’s independence; however, there is no requirement that any adviser be independent.

In February 2025, after taking into consideration the six factors prescribed by the SEC and Nasdaq, the Compensation Committee engaged Aon plc (“Aon”), a compensation consulting platform of Aon Consulting Inc., to perform the services described in “Executive Compensation — Role of Independent Compensation Consultant.” The Compensation Committee has assessed Aon’s independence and determined that Aon had no conflicts of interest in connection with its provision of services to the Compensation Committee in fiscal 2025. The selection of Aon was made without the input or influence of management. Additional information regarding the Compensation Committee’s processes and procedures, including the role of compensation consultants in evaluating the amount or form of executive and director compensation, can be found in the “Executive Compensation” section of this Proxy Statement.

The specific determinations of our Compensation Committee with respect to executive compensation for the year ended December 31, 2025 are described in greater detail in the “Executive Compensation” section of this Proxy Statement.

Nominating and Corporate Governance Committee

The Nominating and Corporate Governance Committee is currently composed of three directors: Mr. Bienaimé (Chair), Mr. Knowles and Dr. Seth. All members of the Nominating and Corporate Governance Committee are independent (as independence is currently defined in Rule 5605(a)(2) of the Nasdaq listing rules). The Nominating and Corporate Governance Committee met five times during 2025. The Nominating and Corporate Governance Committee also acts periodically by unanimous written consent in lieu of a formal meeting. The Board has adopted a written Nominating and Corporate Governance Committee charter that is available to stockholders on our website at ir.kerostx.com.

The principal duties and responsibilities of the Nominating and Corporate Governance Committee include, among other things:

•

identifying individuals qualified to become members of the Board (consistent with criteria approved by the Board);

•

reviewing the qualifications of, and considering stockholders’ recommendations for, director candidates and recommending to the Board qualified director nominees for appointment, election or reelection to the Board at each annual stockholders’ meeting and as necessary to fill vacancies and newly created directorships;

TABLE OF CONTENTS

•

developing and recommending to the Board for adoption the corporate governance guidelines and codes of conduct applicable to the Company;

•

periodically reviewing such guidelines and codes of conduct, recommending changes to the same from time to time as appropriate and overseeing and monitoring compliance with such guidelines and codes;

•

overseeing evaluations of the Board, its committees, and Board members;

•

identifying directors qualified to serve on the various committees of the Board and recommending to the Board qualified nominees for membership on each such committee;

•

overseeing succession planning for the Board and key leadership roles on the Board and its committees; and

•

make other recommendations to the Board regarding affairs relating to the directors of the Company.

The Nominating and Corporate Governance Committee believes that candidates for director should have certain minimum qualifications, including the ability to read and understand basic financial statements and having the highest personal integrity and ethics. The Nominating and Corporate Governance Committee also intends to consider such factors as possessing relevant expertise upon which to be able to offer advice and guidance to management, having a wide range of personal backgrounds, perspectives and experiences, having sufficient time to devote to the affairs of the Company, demonstrated excellence in his or her field, having the ability to exercise sound business judgment, experience as a board member or executive officer of another publicly held company and having the commitment to rigorously represent the long-term interests of our stockholders. However, the Nominating and Corporate Governance Committee retains the right to modify these qualifications from time to time. Candidates for director nominees are reviewed in the context of the current composition of the Board, our operating requirements and the long-term interests of our stockholders. In conducting this assessment, the Nominating and Corporate Governance Committee considers the current needs of the Board and the Company, to maintain a balance of knowledge, experience and capability.

The Nominating and Corporate Governance Committee appreciates the value of thoughtful board refreshment, and regularly identifies and considers qualities, skills and other director attributes that would enhance the composition of the Board. In the case of incumbent directors whose terms of office are set to expire, the Nominating and Corporate Governance Committee reviews these directors’ overall service to the Company during their terms, including the number of meetings attended, level of participation, quality of performance and any other relationships and transactions that might impair the directors’ independence. In the case of new director candidates, the Nominating and Corporate Governance Committee also determines whether the nominee is independent for Nasdaq purposes, which determination is based upon applicable Nasdaq listing standards, applicable SEC rules and regulations and the advice of counsel, if necessary. The Nominating and Corporate Governance Committee then uses its network of contacts to compile a list of potential candidates, but may also engage, if it deems appropriate, a professional search firm. The Nominating and Corporate Governance Committee conducts any appropriate and necessary inquiries into the backgrounds and qualifications of possible candidates after considering the function and needs of the Board. The Nominating and Corporate Governance Committee meets to discuss and consider the candidates’ qualifications and then selects a nominee for recommendation to the Board by majority vote.

The Nominating and Corporate Governance Committee will consider director candidates recommended by stockholders. The Nominating and Corporate Governance Committee does not intend to alter the manner in which it evaluates candidates, including the minimum criteria set forth above, based on whether or not the candidate was recommended by a stockholder. Stockholders who wish to recommend individuals for consideration by the Nominating and Corporate Governance Committee to become nominees for election to the Board may do so by delivering a written recommendation to the Nominating and Corporate Governance Committee at the following address: Keros Therapeutics, Inc., 1050 Waltham Street, Suite 302, Lexington, Massachusetts 02421, Attention: Corporate Secretary, at least 90 days, but no more than 120 days, prior to the anniversary date of the mailing of our proxy statement for the last annual meeting. Submissions must include the name and address of the stockholder on whose behalf the submission is made and any affiliate who controls (as such term is defined in Rule 405 under the Securities Act of 1933, as amended) the foregoing

TABLE OF CONTENTS

stockholder, directly or indirectly, the class, series and number of shares of our capital stock that are, directly or indirectly, owned of record or beneficially by such stockholder as of the date of the submission, a representation whether such stockholder or any other participant will engage in a solicitation with respect to such nomination or proposal and, if so, the name of each participant in such solicitation and the amount of the cost of solicitation that has been and will be borne, directly or indirectly, by each participant in such solicitation. Any such submission must be accompanied by the written consent of the proposed nominee to be named as a nominee and to serve as a director if elected and a completed and signed questionnaire, representation and agreement. You should refer to our amended and restated bylaws for a complete description of the required procedures for nominating a candidate to our Board.

Our Approach to Stockholder Engagement

We understand that engaging with our stockholders is a critical component of our overall governance and business strategy. Our approach is guided by our commitment to accountability, transparency and responsiveness to our investors’ needs and interests. We recognize that our stockholders play a critical role in our success and take their views seriously. Members of our management team regularly engage with many of our largest stockholders throughout the year to better understand their concerns, priorities and expectations. Through these relationships, we have obtained valuable insight on a variety of topics, including our business and growth strategy, corporate governance practices, executive compensation matters and various other environmental, social and governance matters. Our process for stockholder outreach and engagement occurs throughout the year. We hold an annual general meeting each year to provide our stockholders with an opportunity to meet with management and our Board, ask questions, and provide feedback on our business and development strategy. Following our annual stockholder meeting, we review the voting results to gain an initial understanding of areas of focus, and beginning in the fall, we reach out to stockholders to invite feedback and discussion to ensure an understanding of the areas of greatest interest to our stockholders.

Following the 2025 annual meeting, members of our management team and one of our independent directors reached out to a significant number of our large stockholders to gain a better understanding of their views regarding investment stewardship priorities, corporate governance matters and our executive compensation program.

In addition, we conduct regular proactive outreach and accept inbound requests throughout the year offering stockholders time with management, including but not limited to regular corporate updates and one-on-one meetings, reporting of quarterly financial results and operational updates, and presenting and meeting with stockholders at multiple industry and banking conferences. Over the 2025-2026 cycle, areas of particular stockholder interest included the following:

•

The formal review of strategic alternatives to maximize stockholder value for the Company, which was undertaken by the Board;

•

The return of $375 million of excess capital to stockholders;

•

Board refreshment and composition, and related disclosures;

•

Executive compensation, including the importance of alignment between pay and performance, establishing measurable targets and transparent disclosure in respect of compensation decisions; and

•

Ongoing clinical development of our product candidates, rinvatercept and elritercept.

Stockholder Communications with the Board of Directors

Stockholder communications will be reviewed by one or more employees of the Company designated by the Board, who will determine whether the communication should be presented to the Board. The purpose of this screening is to allow the Board to avoid having to consider irrelevant or inappropriate communications (such as advertisements, solicitations and hostile communications). All communications directed to the Audit Committee in accordance with our Whistleblower Policy for Accounting and Auditing Matters that relate to questionable accounting or auditing matters involving the Company will be promptly and directly forwarded to the Audit Committee. We also have a corporate ethics hotline to allow complaints related to

TABLE OF CONTENTS

questionable accounting or auditing matters. All inquiries made through this hotline are immediately directed to the Chair of the Audit Committee.

Code of Business Conduct and Ethics

We have adopted the Keros Therapeutics, Inc. Code of Business Conduct and Ethics that applies to all of our officers, directors and employees. The Code of Business Conduct and Ethics is available on our website at ir.kerostx.com. If we ever were to amend or waive any provision of our Code of Business Conduct and Ethics that applies to our principal executive officer, principal financial officer, principal accounting officer or any person performing similar functions, we intend to satisfy our disclosure obligations, if any, with respect to any such waiver or amendment by posting such information on our website set forth above rather than by filing a Current Report on Form 8-K.

Corporate Governance Guidelines

Our Corporate Governance Guidelines are designed to assure that the Board will have the necessary authority and practices in place to review and evaluate our business operations as needed and to make decisions that are independent of our management. The Corporate Governance Guidelines are also intended to align the interests of directors and management with those of our stockholders. The Corporate Governance Guidelines set forth the practices the Board intends to follow with respect to board composition and member selection, board meetings and involvement of senior management, Chief Executive Officer performance evaluation and succession planning, board committees and compensation and board assessment. The Board regularly monitors developments in corporate governance practices and regulatory changes and periodically assesses the adequacy of and may modify our Corporate Governance Guidelines and committee charters as warranted in light of such developments. The Corporate Governance Guidelines, as well as the charters for each committee of the Board, may be viewed on our website at ir.kerostx.com.

Hedging and Pledging Prohibition

Our Board has adopted the Keros Therapeutics, Inc. Insider Trading Policy, which prohibits any employee or director from engaging in short sales, transactions in put or call options, hedging transactions, margin accounts, pledges or other inherently speculative transactions with respect to our common stock at any time. A copy of our insider trading policy is filed as an exhibit to our Annual Report on Form 10-K for our fiscal year ended December 31, 2025. In addition, it is our intent to comply with applicable laws and regulations relating to insider trading.

TABLE OF CONTENTS

PROPOSAL 2
RATIFICATION OF SELECTION OF INDEPENDENT REGISTERED
PUBLIC ACCOUNTING FIRM

The Audit Committee has selected Deloitte & Touche LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2026 and has further directed that management submit the selection of our independent registered public accounting firm for ratification by the stockholders at the Annual Meeting. Deloitte & Touche LLP has audited our financial statements since 2019. Representatives of Deloitte & Touche LLP are expected to be present at the Annual Meeting. They will have an opportunity to make a statement if they so desire and will be available to respond to appropriate questions.

Neither our bylaws nor other governing documents or applicable law require stockholder ratification of the selection of Deloitte & Touche LLP as our independent registered public accounting firm. However, the Audit Committee is submitting the selection of Deloitte & Touche LLP to the stockholders for ratification as a matter of good corporate practice. If the stockholders fail to ratify the selection, the Audit Committee will reconsider whether or not to retain that firm. Even if the selection is ratified, the Audit Committee in its discretion may direct the appointment of a different independent registered public accounting firm at any time during the year if they determine that such a change would be in the best interests of the Company and our stockholders.

Vote Required

The affirmative vote of the holders of a majority of the shares present by virtual attendance or represented by proxy and entitled to vote on the matter at the Annual Meeting will be required to ratify the selection of Deloitte & Touche LLP.

Principal Accountant Fees and Services

The following table represents aggregate fees billed to us for the fiscal years ended December 31, 2025 and 2024 by Deloitte & Touche LLP.

	Fiscal Year Ended
	2025			2024
Audit Fees(1)		$	995,000		$	1,231,657
Audit-Related Fees			—			—
Tax Fees			—			—
Other Fees(2)		$	1,895		$	1,895
Total Fees		$	996,895		$	1,233,552

(1)

Audit fees consist of fees billed for professional services provided in connection with the audit of our annual financial statements, the review of our quarterly financial statements and audit services that are normally provided by independent registered public accounting firm in connection with regulatory filings. The audit fees also include fees for professional services provided in connection with our SEC registration statements incurred during the fiscal years ended December 31, 2025 and 2024, including comfort letters, consents and review of documents filed with the SEC.

(2)

Other fees consist of the subscription fee to the Deloitte & Touche LLP Research Tool Library.

All fees described above were pre-approved by the Audit Committee.

Pre-Approval Policies and Procedures

The Audit Committee has adopted a policy and procedures for the pre-approval of audit and non-audit services rendered by our independent registered public accounting firm, Deloitte & Touche LLP. The policy generally permits pre-approval of specified services in the defined categories of audit services, audit-related services, tax services and non-audit services. Pre-approval may also be given as part of the Audit Committee’s

TABLE OF CONTENTS

approval of the scope of the engagement of the independent registered public accounting firm or on an individual, explicit, case-by-case basis before the independent registered public accounting firm is engaged to provide each service. The pre-approval of services may be delegated to one or more of the Audit Committee’s members, but the decision must be reported to the full Audit Committee at its next scheduled meeting.

The Audit Committee has determined that the rendering of services other than audit services by Deloitte & Touche LLP is compatible with maintaining the principal accountant’s independence.

THE BOARD OF DIRECTORS UNANIMOUSLY RECOMMENDS A VOTE “FOR” PROPOSAL 2.

TABLE OF CONTENTS

PROPOSAL 3
ADVISORY VOTE ON NAMED EXECUTIVE OFFICER COMPENSATION

The Board recognizes the interests our investors have in the compensation of our NEOs. In recognition of that interest and as required by the Dodd-Frank Wall Street Reform and Consumer Protection Act (the “Dodd-Frank Act”), Section 14A of the Exchange Act and the related rules of the SEC, we are providing our stockholders with the opportunity to vote to approve, on an advisory basis, non-binding vote, the compensation of our NEOs as disclosed in this Proxy Statement in accordance with SEC rules and Item 402 of Regulation S-K, including the Executive Compensation, compensation tables, and narrative discussion. In considering their vote, we urge stockholders to review the information on our compensation policies and decisions regarding the named NEOs presented in Executive Compensation beginning on page 28 of this Proxy Statement.

This advisory resolution, commonly known as a “say-on-pay” proposal, is non-binding. Although this resolution is non-binding, the resolution gives our stockholders the opportunity to express their views on our NEOs’ compensation as a whole. This vote is not intended to address any specific item of compensation, but rather the overall compensation of our NEOs and the philosophy, policies and practices described in this Proxy Statement. The compensation of our NEOs subject to the vote is disclosed in Executive Compensation, the compensation tables, and the related narrative disclosure contained in this Proxy Statement. As discussed in those disclosures, we believe that our compensation policies and decisions are based on principles that reflect a “pay-for-performance” philosophy and are strongly aligned with our stockholders’ interests and consistent with current market practices. Compensation of our NEOs is designed to enable us to attract and retain talented and experienced executives to lead us successfully in a competitive environment. We expect that we will conduct our next say-on-pay vote at the 2027 annual meeting of stockholders.

Accordingly, the Board is asking our stockholders to indicate their support for the compensation of our NEOs as described in this Proxy Statement by casting an advisory, non-binding vote “FOR” the following resolution:

“RESOLVED, that the compensation paid to the Company’s named executive officers, as disclosed pursuant to Item 402 of Regulation S-K, including the Executive Compensation, compensation tables and narrative discussion, is hereby APPROVED.”

Because the vote is advisory, the result is not binding on the Board or Compensation Committee. Nevertheless, the views expressed by our stockholders, whether through this say-on-pay vote or otherwise, are important to management and the Board and, accordingly, the Board and the Compensation Committee intend to consider the results of this vote in making determinations in the future regarding executive compensation arrangements.

Vote Required

Advisory, non-binding approval of Proposal 3 requires the approval of the holders of a majority of shares present by remote communication or represented by proxy and entitled to vote at the Annual Meeting.

THE BOARD OF DIRECTORS UNANIMOUSLY RECOMMENDS A VOTE “FOR” PROPOSAL 3.

TABLE OF CONTENTS

SECURITY OWNERSHIP OF
CERTAIN BENEFICIAL OWNERS AND MANAGEMENT

The following table sets forth certain information regarding the ownership of our common stock as of March 31, 2026 by:

•

each person, or group of affiliated persons, who is known by us to beneficially own more than 5% of our common stock;

•

each of our directors;

•

each of our NEOs; and

•

all of our current executive officers and directors as a group.

Beneficial ownership is determined according to the rules of the SEC and generally means that a person has beneficial ownership of a security if he, she or it possesses sole or shared voting or investment power of that security, or has the right to acquire beneficial ownership of that security within 60 days. Unless otherwise indicated below, to our knowledge, the persons and entities named in the table have sole voting and sole investment power with respect to all shares that they beneficially owned, subject to community property laws where applicable.

Our calculation of the percentage of beneficial ownership is based on 19,732,837 shares of common stock outstanding on March 31, 2026. Shares of common stock issuable under stock options that are currently exercisable or exercisable within 60 days of March 31, 2026 are deemed beneficially owned, and such shares are used in computing the percentage ownership of the person holding these options or restricted stock unit awards (“RSU”) and the percentage ownership of any group of which the holder is a member but are not deemed outstanding for computing the percentage of any other person.

This table is based upon information supplied by our officers, directors and principal stockholders and Schedules 13D and 13G filed with the SEC. Except as otherwise noted below, the address for each executive officer and director listed in the table is c/o Keros Therapeutics, Inc., 1050 Waltham Street, Suite 302, Lexington, Massachusetts 02421.

Beneficial Owner	Number of Shares Beneficially Owned		Percent of Shares Beneficially Owned
Greater than 5% Stockholders
BlackRock, Inc.(1)		1,990,842		10.1%
Directors and Named Executive Officers
Jasbir Seehra, Ph.D.(2)		1,871,682		8.8
Keith Regnante(3)		235,983		1.2
Esther Cho(4)		144,993		*
Christopher Rovaldi(5)		—		—
Jean-Jacques Bienaimé(6)		20,341		*
Nima Farzan(7)		52,961		*
Mary Ann Gray, Ph.D.(8)		61,048		*
Julius Knowles(9)		297,932		1.5
Charles Newton(10)		1,101		*
Alpna Seth(11)		47,875		*
All current executive officers and directors as a group (10 persons)(12)		2,771,034		12.6%

Less than one percent.

(1)

The information shown is based solely upon disclosures filed on a Schedule 13G filed on April 7, 2026 by BlackRock, Inc. The address of BlackRock, Inc. is 50 Hudson Yards, New York, NY 10001.

TABLE OF CONTENTS

(2)

Consists of (i) 312,498 shares of common stock held by Dr. Seehra and (ii) 1,559,184 shares issuable upon the exercise of options granted to Dr. Seehra that are exercisable within 60 days of March 31, 2026.

(3)

Consists of (i) 9,781 shares of common stock held by Mr. Regnante and (ii) 226,202 shares issuable upon the exercise of options granted to Mr. Regnante that are exercisable within 60 days of March 31, 2026.

(4)

Consists of (i) 10,275 shares of common stock held by Ms. Cho and (ii) 134,718 shares issuable upon the exercise of options granted to Ms. Cho that are exercisable within 60 days of March 31, 2026.

(5)

Mr. Rovaldi ceased his employment with the Company, effective August 18, 2025. Beneficial ownership information is based on information known to us.

(6)

Consists of (i) 2,200 shares of common stock held by Mr. Bienaimé and (ii) 18,141 shares issuable upon the exercise of options granted to Mr. Bienaimé that are exercisable within 60 days of March 31, 2026.

(7)

Consists of shares issuable upon the exercise of options granted to Mr. Farzan that are exercisable within 60 days of March 31, 2026.

(8)

Consists of shares issuable upon the exercise of options granted to Dr. Gray that are exercisable within 60 days of March 31, 2026.

(9)

Consists of (i) 150,047 shares of common stock held by Partners Innovation Fund, LLC (“PIF I”), (ii) 102,233 shares of common stock held by Partners Innovation Fund II, L.P. (“PIF II”), (iii) 1,191 shares of common stock held by Mr. Knowles and (iv) 44,461 shares issuable upon the exercise of options granted to Mr. Knowles that are exercisable within 60 days of March 31, 2026. PIF I and PIF II are collectively referred to as the “Partners Entities.” Partners Innovation Fund, LLC (“Partners GP I”) is the ultimate general partner of PIF I, and Partners Innovation Fund II, LLC (“Partners GP II”) is the ultimate general partner of PIF II. Julius Knowles, a member of our Board, is a partner of each of Partners GP and Partners GP II, and, as a result, may be deemed to share voting and investment power with respect to the shares held by each of the Partners Entities. The address of each of the Partners Entities is 399 Revolution Drive, Suite 999, Somerville, Massachusetts 02145.

(10)

Mr. Newton was appointed to the Board, effective March 9, 2026. Consists of shares issuable upon the vesting of RSUs granted to Mr. Newton within 60 days of March 31, 2026.

(11)

Consists of shares issuable upon the exercise of options granted to Dr. Seth that are exercisable within 60 days of March 31, 2026.

(12)

Consists of (i) 595,902 shares of common stock, (ii) 2,174,031 shares issuable upon the exercise of options granted to our current executive officers and directors that are exercisable within 60 days of March 31, 2026 and (iii) 1,101 shares issuable upon the vesting of RSUs granted to our current executive officers and directors that are exercisable within 60 days of March 31, 2026.

TABLE OF CONTENTS

EXECUTIVE OFFICERS

The following table sets forth, for our executive officers, their ages and position held with us as of the date of this Proxy Statement:

Name	Age	Principal Position
Jasbir Seehra, Ph.D.	70	President and Chief Executive Officer
Keith Regnante	56	Chief Financial Officer
Esther Cho, Esq.	37	Chief Legal Officer
Lorena Lerner, Ph.D.	54	Chief Scientific Officer

Biographical information for Dr. Seehra is presented above under the caption “Class I Directors Continuing in Office Until the 2027 Annual Meeting of Stockholders.”

Keith Regnante has served as our Chief Financial Officer since February 2020. Prior to joining us, from August 2016 to January 2020, Mr. Regnante served as Chief Financial Officer at Wave Life Sciences Ltd. From February 2014 to August 2016, Mr. Regnante served as Vice President of Finance at Shire Pharmaceuticals, or Shire, a global biopharmaceutical company. Mr. Regnante also served on the Financial Leadership Team and the R&D Leadership Team while he was at Shire. From September 2013 to February 2014, he served as Head of R&D Finance for ARIAD Pharmaceuticals, Inc. From January 1999 to August 2013, Mr. Regnante held multiple finance positions at Biogen Inc., including Senior Director of Corporate Finance from 2011 to 2013, Senior Director of Worldwide R&D Finance from 2008 to 2011 and several other positions dating back to 1999. Prior to these roles, Mr. Regnante worked as a consultant at The Boston Consulting Group. He holds a B.A. in Economics from Tufts University and an M.B.A. from the MIT Sloan School of Management.

Esther Cho, Esq., has served as our Chief Legal Officer since February 2026, and also serves as our Secretary. Prior to that, Ms. Cho served as our Senior Vice President, General Counsel beginning in February 2023, and previously served as our Vice President, Head of Legal beginning in April 2020. Prior to joining us, Ms. Cho was an associate at Cooley LLP, where she represented public and private companies in biotechnology and other industries across a range of capital markets and strategic transactions throughout their lifecycle. Ms. Cho received a J.D. from Boston University School of Law and a B.A. in History from University of Pennsylvania.

Lorena Lerner, Ph.D., has served as our Chief Scientific Officer since August 2025. Prior to that, Dr. Lerner served as our Senior Vice President, Research beginning in January 2024, and previously served as our Vice President, Research beginning in May 2022. From September 2017 to May 2022, Dr. Lerner held multiple positions of increasing responsibility at Oncorus, Inc., including Senior Director, Molecular Biology from September 2017 to December 2018, Vice President, Molecular Biology from January 2019 to November 2021 and Vice President, Research from December 2021 to May 2022. Prior to Oncorus, Inc., Dr. Lerner worked at Quiet Therapeutics from 2016 to 2017, at Scholar Rock Holding Corporation from 2015 to 2016 and at AVEO Pharmaceuticals, Inc. from 2003 to 2015. Dr. Lerner received an M.S. in Molecular Biology and a Ph.D. in Biochemistry from the University of Buenos Aires. She completed her postdoctoral work at The Rockefeller University.

TABLE OF CONTENTS

EXECUTIVE COMPENSATION

Smaller Reporting Company Status

We qualify as a “smaller reporting company” under rules promulgated by the SEC. As a result, we are permitted to and rely on exemptions from certain disclosure requirements that are applicable to other companies that are not smaller reporting companies. Accordingly, we have included compensation information for only our principal executive officer during 2025, our two next most highly compensated executive officers serving at 2025 fiscal year-end, and a former executive officer who would have been among our two highly compensated executive officers for the year ended December 31, 2025 but for the fact that such individual was not serving as an executive officer at the end of the year ended December 31, 2025, and have not included tabular compensation information other than the Summary Compensation Table and the Outstanding Equity Awards at 2025 Year End table or a compensation discussion and analysis of our executive compensation programs. We have, however, included an expanded discussion of compensation decisions with respect to our named executive officers below.

Named Executive Officers

Our named executive officers for the fiscal year ended December 31, 2025, are our principal executive officer and our two other most highly compensated executive officers who were serving as executive officers as of December 31, 2025, and one executive officer who would have been among our two highly compensated executive officers for the year ended December 31, 2025 but for the fact that such individual was not serving as an executive officer at the end of the year ended December 31, 2025, as reflected below.

•

Jasbir Seehra, Ph.D., President and Chief Executive Officer(1);

•

Keith Regnante, Chief Financial Officer;

•

Esther Cho, Esq., Chief Legal Officer and Secretary(2); and

•

Christopher Rovaldi, former President and Chief Operating Officer(3).

(1)

Dr. Seehra was appointed to the additional position of President, effective August 18, 2025. Additionally, Dr. Seehra ceased serving as Chair of our Board, effective as of August 18, 2025, but continued to serve as a member of the Board.

(2)

Ms. Cho was promoted to the position of Chief Legal Officer, effective February 24, 2026.

(3)

Mr. Rovaldi ceased serving as our President and Chief Operating Officer, effective August 18, 2025.

Executive Summary

Business Overview

We are a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta (“TGF-ß”) family of proteins. We are a leader in understanding the role of the TGF-ß family of proteins, which are master regulators of the growth, repair and maintenance of a number of tissues, including blood, bone, skeletal muscle, adipose and heart tissue. By leveraging this understanding, we have discovered and are developing protein therapeutics that have the potential to provide meaningful and potentially disease-modifying benefit to patients. Our lead product candidate, rinvatercept (KER-065), is being developed for the treatment of Duchenne muscular dystrophy (“DMD”) and for the treatment of amyotrophic lateral sclerosis. Our most advanced product candidate, elritercept (KER-050), is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes (“MDS”) and in patients with myelofibrosis. In December 2024, we entered into an exclusive license agreement with Takeda Pharmaceuticals U.S.A., Inc. to further develop, manufacture and commercialize elritercept worldwide outside of mainland China, Hong Kong and Macau, which became effective on January 16, 2025 (the “Takeda Agreement”).

TABLE OF CONTENTS

Compensation Highlights for 2025

We carefully evaluate our compensation arrangements and maintain and develop programs that we feel are the most appropriate to drive results for our Company and our stockholders. We take a holistic approach to designing our policies to align our executive compensation program with our stockholders’ interests and our Company performance, which is best viewed over the long-term to align with product development cycles. Highlights of our executive compensation program in 2025 and early 2026 pay decisions include:

•

Base Salary: Our named executive officers’ base salaries for 2025 increased between 0% and 8% as compared to 2024 levels. These changes were aligned with broader Company actions and reflected the Company’s performance and market positioning when 2025 target compensation was approved in early 2025.

•

Annual Cash Performance Bonus: We did not increase target bonus award opportunities for our named executive officers for 2025. In February 2026, the Compensation Committee determined that our 2025 performance goals were achieved at 87.5% and paid performance-based bonuses at 87.5% of target to each of Dr. Seehra, Mr. Regnante and Ms. Cho.

•

Long-Term Incentive Awards: In 2025, we granted equity awards to each of Dr. Seehra, Mr. Regnante, Ms. Cho and Mr. Rovaldi in the form of RSUs in order to retain our named executive officers and incentivize and reward them for stockholder value creation. The RSUs granted to Dr. Seehra vest as follows: 50% is subject to four-year time-vesting and 50% is eligible to vest contingent upon achievement of two rigorous pipeline development goals that are aligned with the Company’s corporate strategy. The RSUs granted to Mr. Regnante, Ms. Cho and Mr. Rovaldi are subject to time-vesting.

Compensation Program Objectives, Philosophy and Elements of Compensation

Our Compensation Committee is guided by the following objectives and principles when establishing compensation for our executive officers:

•

Attract, retain and motivate superior executive talent;

•

Provide incentives that reward the achievement of performance goals that directly correlate to the enhancement of stockholder value, as well as to facilitate executive retention; and

•

Align our executives’ interests with those of our stockholders through long-term incentives linked to specific performance.

We believe that our executive compensation program design features accomplish the following:

•

Provide base salaries consistent with each executive’s responsibilities so that they are not motivated to take excessive risks to achieve a reasonable level of financial security.

•

Ensure a significant portion of each executive’s compensation is tied to our future share performance, thus aligning their interests with those of our stockholders.

•

Utilize equity compensation and vesting periods for equity awards that encourage executives to remain employed and focus on sustained share price appreciation.

•

Utilize a mix between cash and equity compensation designed to encourage strategies and actions that are in our long-term best interests.

TABLE OF CONTENTS

To achieve our compensation objectives, we historically have provided our executive officers, including our named executive officers, with a compensation package consisting of the following elements:

Element of Compensation	Objectives	Key Features
Base Salary (fixed cash)	Provides financial stability and security through a fixed amount of cash for performing job responsibilities.	Generally reviewed annually at the beginning of the year and determined based on a number of factors (including individual performance, internal equity, retention, expected cost of living increases and our overall performance) and by reference to market data provided by our independent compensation consultant.
Performance Bonus (at-risk cash)	Motivates and rewards for attaining rigorous annual performance goals that relate to our key business objectives.	Target bonus amounts, calculated as a percentage of base salary, are generally reviewed annually at the beginning of the year and determined based upon positions that have similar impact on the organization, the executive’s position criticality and experience in role and competitive bonus opportunities in our market. Bonus opportunities are dependent upon achievement of specific performance objectives, generally determined by our Compensation Committee and Board and communicated at the beginning of the year. Actual bonus amounts earned are determined after the end of the year, based on achievement of the designated performance objectives and individual performance.
Long-Term Incentive (at-risk equity)	Motivates and rewards for long-term Company performance. Aligns executives’ interests with stockholder interests and changes in stockholder value. Attracts highly qualified executives and encourages their continued employment over the long-term.	Annual equity opportunities are generally reviewed and determined annually at the beginning of the year or as appropriate during the year for new hires, promotions, or other special circumstances, such as to encourage retention, or as a reward for significant achievement. Individual grants are determined based on a number of factors, including current corporate and individual performance, outstanding equity holdings and their retention value

TABLE OF CONTENTS

Element of Compensation			Objectives			Key Features
						and total ownership, historical value of our stock, internal equity amongst executives, aggregate equity usage and market data provided by our independent compensation consultant. Equity awards have historically been granted in the form of time-vesting stock options. In 2024, we introduced performance-vesting stock options into our Chief Executive Officer’s compensation program. In 2025, we introduced time-vesting RSU awards into our executive compensation program, and performance-vesting RSUs into our Chief Executive Officer’s compensation program.

In evaluating our executive compensation policies and programs, as well as the short-term and long-term value of our executive compensation plans, we consider both the performance and skills of each of our executives, as well as the compensation paid to executives in similar companies with similar responsibilities. We focus on providing a competitive compensation package which provides significant short-term and long-term incentives for the achievement of measurable corporate objectives. We believe that this approach provides an appropriate blend of short-term and long-term incentives to maximize stockholder value.

We do not have any formal policies for allocating compensation among salary, performance bonus awards and equity grants, short-term and long-term compensation or among cash and non-cash compensation. Instead, our Compensation Committee uses its judgment to establish a total compensation program for each named executive officer that is a mix of current, short-term incentive and long-term incentive compensation, and cash and non-cash compensation, that it believes appropriate to achieve the goals of our executive compensation program and our corporate objectives. However, a significant portion of the named executive officers’ total target compensation is comprised of performance-based bonus opportunities and long-term equity awards to align the executive officers’ incentives with the interests of our stockholders and our corporate goals.

In making executive compensation recommendations and decisions, our Compensation Committee generally considers each executive officer’s target total direct compensation, which consists of base salary, target bonus opportunity, which together with base salary we refer to as target cash compensation, and long-term equity awards (valued based on an approximation of grant date fair value).

TABLE OF CONTENTS

Key Features of our Executive Compensation Program

What We Do		What We Don’t Do
√	Design executive compensation to align pay with performance	X	No hedging or pledging of Company stock
√	Conduct a thorough compensation risk analysis	X	No excessive health or welfare benefits or perquisites
√	Grant annual equity awards over multi-year vesting periods	X	No special retirement benefits
√	Grant performance equity awards to our Chief Executive Officer	X	No guaranteed bonuses or base salary increases
√	Compensation Committee composed of all independent directors, which meets regularly in independent session without management present
√	Retain an independent compensation consultant
√	Maintain stock ownership guidelines
√	Maintain a clawback policy
√	Conduct an annual compensation review
√	Conduct an annual say-on-pay vote

How We Determine Executive Compensation

Role of Our Compensation Committee, Management and the Board

Our Compensation Committee is appointed by our Board to assist with our Board’s oversight responsibilities with respect to our compensation and benefit plans, policies and programs, administration of our equity plans and its responsibilities related to the compensation of our executive officers, directors and senior management, as appropriate.

Our Compensation Committee is primarily responsible for establishing and reviewing our overall compensation strategy. Our Compensation Committee meets periodically throughout the year to, among other responsibilities, manage and evaluate our executive compensation program. In this capacity, our Compensation Committee designs, implements, reviews and generally recommends to our Board the approval of all compensation for our Chief Executive Officer and our other named executive officers. Our Compensation Committee determines and recommends the principal components of compensation (base salary, performance bonus awards and equity awards) for our executive officers on an annual basis; however, decisions may occur at other times for new hires, promotions or other special circumstances as our Compensation Committee or our Board determines appropriate. The Compensation Committee does not delegate authority to approve executive officer compensation.

In addition to our independent compensation consultant, as described below under “Role of Independent Compensation Consultant,” our Compensation Committee works with and receives information and analyses from management, including within our legal and human resources departments, and our Chief Executive Officer, and considers such information and analyses along with the information from our independent compensation consultant, in determining the structure and amount of compensation to be paid to our executive officers, including our named executive officers. Our Chief Executive Officer evaluates and provides to our Compensation Committee executive officer performance assessments and management’s recommendations and proposals regarding executive officer compensation programs and decisions affecting base salaries, performance incentives, equity compensation and other compensation-related matters

TABLE OF CONTENTS

outside of the presence of any other named executive officers. Members of management, including our Chief Executive Officer, may attend portions of our Compensation Committee’s meetings. However, our Compensation Committee retains the final authority to make all compensation decisions and recommendations. While our Chief Executive Officer discusses his recommendations with our Compensation Committee, he does not participate in the deliberations concerning, or the determination of, his own compensation.

From time to time, various other members of management and other employees as well as outside advisors or consultants may be invited by our Compensation Committee to make presentations, provide financial or other background information or advice or otherwise participate in Compensation Committee or Board meetings.

Role of Independent Compensation Consultant

During 2025, our Compensation Committee continued to retain Aon’s Human Capital Solutions practice, a division of Aon, as our independent compensation consultant, due to its extensive analytical and compensation expertise. In this capacity, Aon has advised our Compensation Committee on compensation matters related to the executive and director compensation structure. In 2025, Aon assisted with, among other things:

•

conducting an executive market pay analysis;

•

developing a group of peer companies to use as a reference in making executive compensation decisions;

•

evaluating current executive pay practices and considering alternative compensation programs;

•

reviewing our director compensation policies and practices;

•

evaluating the adoption of and reviewing our stock ownership guidelines; and

•

assisting in the development of this Executive Compensation analysis.

Our Compensation Committee has the sole authority to engage and terminate Aon’s services, as well as to approve its compensation. Aon makes recommendations to our Compensation Committee, but has no authority to make compensation decisions on behalf of us or our Compensation Committee. Aon reported to our Compensation Committee and had direct access to the chairperson and the other members of our Compensation Committee. Beyond data and advice related to executive and director compensation matters, Aon did not provide other services to us in 2025.

Our Compensation Committee has analyzed whether the work of Aon as our compensation consultant raised any conflict of interest, considering relevant factors in accordance with SEC guidelines. Based on its analysis, our Compensation Committee determined that the work of Aon and the individual compensation advisors has not created any conflict of interest.

Use of Competitive Market Compensation Data

Our Compensation Committee believes that it is important when making compensation decisions to be informed as to the current practices of comparable public companies with which we compete for top talent. To this end, our Compensation Committee works annually with Aon to review and amend the list of our peer group companies to be used in connection with assessing compensation practices and pay levels. Our Compensation Committee believes that the peer and market data provided by Aon, along with other factors (including experience, scope of position and individual performance), is an important reference point when setting compensation for our named executive officers because competition for executive management is intense in our industry and the retention of our talented leadership team is critical to our success.

TABLE OF CONTENTS

2025 Peer Group

In September 2024, Aon proposed, and our Compensation Committee approved, a group of companies that would be appropriate peers for 2025 compensation decisions, based on the following criteria:

•

Sector: Biopharmaceuticals and biotechnology companies

•

Stage of Development: Phase II and Phase III companies

•

Market Capitalization: 0.3x to 3x of our 30-day average market value

•

Headcount: 0.3x to 3x of our headcount (as of the end of our last fiscal year)

•

Years Public: Preference given to companies that went public within the last five years

At the time of review in September 2024, our 30-day average market capitalization was approximately $1.7 billion and our prior fiscal year-end headcount was 176. Based on the above criteria, our Compensation Committee approved the following changes to the executive compensation peer group for 2025:

•

Added Celldex Therapeutics, Inc., Disc Medicine, Inc., Longboard Pharmaceuticals, Inc., Pliant Therapeutics, Inc. and Relay Therapeutics, Inc.;

•

Removed Editas Medicine, Inc., Mersana Therapeutics, Inc. and Zentalis Pharmaceuticals, Inc., because they were well below the market capitalization parameters described above; and

•

Removed Morphic Holding Inc., as it was acquired in August 2024.

As a result, the Compensation Committee approved the following 19 companies as our 2025 executive compensation peer group. At the time of the review, our market capitalization was approximately at the 50th percentile of this group.

Akero Therapeutics, Inc. (AKRO)	Iovance Biotherapeutics, Inc. (IOVA)	Replimune Group, Inc. (REPL)
Arcturus Therapeutics Holdings Inc. (ARCT)	KalVista Pharmaceuticals, Inc. (KALV)	Rocket Pharmaceuticals, Inc. (RCKT)
Celldex Therapeutics, Inc. (CLDX)	Kura Oncology, Inc. (KURA)	Scholar Rock Holding Corporation (SRRK)
Crinetics Pharmaceuticals, Inc. (CRNX)	Longboard Pharmaceuticals, Inc. (LBPH)	SpringWorks Therapeutics, Inc. (SWTX)
Disc Medicine, Inc. (IRON)	Pliant Therapeutics, Inc. (PLRX)	Syndax Pharmaceuticals Inc. (SNDX)
Geron Corporation (GERN)	Protagonist Therapeutics, Inc. (PTGX)
IDEAYA Biosciences, Inc. (IDYA)	Relay Therapeutics, Inc. (RLAY)

Subsequent to the Compensation Committee’s approval of the above peer group in September 2024, the Company’s market capitalization declined substantially. As a result, Aon utilized a new industry comparator group based on companies with market capitalizations between $250.0 million and $2.0 billion. At the time of review, we fell at approximately the 50th percentile of the new industry comparator group in terms of market capitalization.

TABLE OF CONTENTS

Key Factors Used in Determining Executive Compensation

Our Compensation Committee formulates recommendations regarding the compensation of our executive officers at levels it determines to be competitive and appropriate for each executive officer, using the professional experience and independent judgment of Compensation Committee members, as well as their understanding of the compensation practices in the biopharmaceutical industry. Pay decisions are not made by use of a formulaic approach or benchmark. In making executive compensation determinations, our Compensation Committee generally takes into consideration the following factors:

•

Company performance and business needs

•

Market data and peer data provided by Aon

•

The need to attract and retain talent in a highly competitive industry

•

The executive officer’s individual performance, experience level, scope of job function and criticality of the skill set

•

Stockholder feedback regarding our executive pay program

•

Input from our Chief Executive Officer (other than for himself)

•

Each executive officer’s current equity ownership and total compensation

•

Internal pay equity

•

The impact of aggregate compensation on the annual budget and on stockholder dilution

Stockholder Advisory Vote on Executive Compensation

We held a “say on pay” advisory vote at our 2025 Annual Meeting of Stockholders, and our stockholders approved, on an advisory basis, the compensation of our named executive officers, as disclosed in our 2025 proxy statement. The proposal was supported by approximately 78% of the total votes cast. Following the 2025 Annual Meeting of Stockholders, members of our management team, including our Chief Financial Officer, Chief Legal Officer and Director, Investor Relations, and one of our independent directors reached out to certain of our stockholders to gain a better understanding of their views regarding corporate governance matters and our executive compensation program. In this process, we reached out to our 30 largest stockholders, representing approximately 85% of outstanding shares of our common stock, resulting in meetings with one stockholder, representing 8% of outstanding shares. In addition to this targeted outreach, we engage with our stockholders on an ongoing basis throughout the year to provide updates on our executive compensation program and corporate governance practices and to solicit stockholder feedback on these matters. During these engagement discussions, we sought to understand our stockholders’ perspectives on a range of topics, including the alignment between our executive pay program and Company performance, establishing measurable targets and transparent disclosure in respect of compensation decisions.

The feedback we received from these conversations was largely constructive and supportive of our compensation program’s overall design and philosophy. The discussions confirmed that the level of “say on pay” support received at the 2025 Annual Meeting of Stockholders was not indicative of fundamental concerns with the structure or design of our executive compensation program.

Our Compensation Committee reviewed the final vote results for our “say on pay” proposal, considered stockholder feedback received during our engagement process and concluded that our compensation program provided a competitive performance package that incentivizes our named executive officers and encourages their retention over the long-term. Accordingly, the Compensation Committee determined not to make any significant changes to our executive compensation policies or decisions as a result of the vote; however, our Compensation Committee determined to monitor and continually evaluate our compensation program going forward in light of our stockholders’ views and our transforming business needs. Our Compensation Committee expects to continue to consider the outcome of our “say on pay” votes and our stockholders’ views when making future compensation decisions for our named executive officers. For additional information regarding our stockholder outreach and engagement efforts, see “Our Approach to Stockholder Engagement” above.

TABLE OF CONTENTS

Elements of Our 2025 Executive Compensation Program

Base Salaries

The base salaries of our named executive officers are an important part of their total compensation package, and are intended to provide a fixed component of compensation reflecting the executive’s skill set, experience, role and responsibilities. Base salaries for our named executive officers have generally been set at levels deemed necessary to attract and retain individuals with superior talent.

In February 2025, upon the recommendation of our Compensation Committee, our Board reviewed the base salaries of our named executive officers and approved increases to base salaries in amounts ranging from approximately 0% to 8% for each of our named executive officers. Based on our Compensation Committee’s subjective judgement, our Compensation Committee determined these increases were appropriate in light of each executive’s individual performance and peer data. The 2025 base salaries of our named executive officers are reflected below.

Named Executive Officer	2024 Base Salary			2025 Base Salary			Percentage Increase from 2024 Base Salary
Jasbir Seehra, Ph.D.		$	700,000		$	700,000	0%
Keith Regnante		$	448,050		$	471,000	5%
Esther Cho, Esq.		$	430,000		$	460,000	7%
Christopher Rovaldi(1)		$	540,000		$	580,000	8%

(1)

Mr. Rovaldi ceased serving as our President and Chief Operating Officer, effective August 18, 2025.

Annual Cash Performance Bonus

Bonus Targets for 2025

Each of our named executive officers is eligible to receive an annual performance bonus based on the achievement of Company-wide annual performance goals determined by our Compensation Committee. Each named executive officer is assigned a target bonus expressed as a percentage of his base salary. The Compensation Committee and Board determined that the bonus targets from 2024 for our named executive officers remained aligned with competitive trends and appropriate for the Company, and as a result, were unchanged for 2025. As such, the target bonus amounts for Dr. Seehra, Mr. Regnante, Ms. Cho and Mr. Rovaldi for 2025 were set at 65%, 40%, 40% and 50%, respectively.

2025 Performance Goals and Achievement

In February 2025, upon the recommendation of our Compensation Committee, our Board adopted our 2025 annual performance goals. The 2025 performance goals were aggressive and set at challenging levels such that the attainment of executive target annual cash incentive award opportunities was not assured at the time they were set and would require a high level of effort and execution on the part of the executive officers and others in order to achieve the goals. The Compensation Committee believes that each of these goals is strongly aligned to the creation of stockholder value.

To determine our corporate performance percentage for 2025, the Compensation Committee employed a holistic analysis that took into account both the extent to which the performance goals had been achieved or exceeded, as well as the relative difficulty of achieving the goals that were met and that were only partially met. Based on the foregoing, the Compensation Committee determined our overall corporate performance achievement percentage to be 87.5% of the target performance level for 2025. The table below

TABLE OF CONTENTS

provides additional details about the Compensation Committee’s assessment of our actual performance against our key 2025 corporate performance goals:

2025 Corporate Objectives	Weight	2025 Achievement Highlights	Overall Weighted Achievement(1)
Advance clinical development of cibotercept:	20%	Advance clinical development of cibotercept:	10%
• Analyze topline data from our Phase 2 clinical trial evaluating cibotercept in patients with PAH (the “TROPOS trial”)		• Achieved
• Decide on development strategy for cibotercept		• Achieved
• Advance cibotercept into another clinical trial		• Not Achieved
Stretch Goal	5%	Stretch Goal	0%
• Achieve a regulatory milestone for cibotercept		• Not Achieved
Advance clinical development of rinvatercept (KER-065):	25%	Advance clinical development of rinvatercept:	20%
• Present initial data from the Phase 1 clinical trial of rinvatercept in healthy volunteers		• Achieved
• Engage and seek input from key external parties regarding the rinvatercept development plan in DMD		• Achieved
• Advance rinvatercept into a Phase 2 clinical trial in patients with DMD		• Partially achieved
Stretch Goals	15%	Stretch Goals	0%
• Achieve two additional development milestones related to DMD and a second neuromuscular indication		• Not Achieved
Elritercept program goals:	15%	Elritercept program goals:	15%
• Screen the first patient in the Phase 3 clinical trial in patients with MDS (the “RENEW trial”)		• Achieved

TABLE OF CONTENTS

2025 Corporate Objectives	Weight	2025 Achievement Highlights	Overall Weighted Achievement(1)
• Transition certain elritercept development responsibilities to Takeda Pharmaceuticals U.S.A., Inc. by the fourth quarter of 2025		• Achieved
Stretch Goal	7.5%	Stretch Goal	7.5%
• Transition certain elritercept development responsibilities to Takeda Pharmaceuticals U.S.A., Inc. by the third quarter of 2025		• Achieved
Advance the discovery pipeline	15%	• Expanded understanding of activin and ligand traps to support development in current indications and to provide rationale for new indications	10%
Stretch Goal	5%	Stretch Goal	0%
		• Not Achieved
Business/Financial Operations	25%	Business/Financial Operations	25%
• Manage the Company’s budget within targeted range		• Achieved
• Develop corporate strategy to expand pipeline in neuromuscular diseases
• Develop business development strategy
Stretch Goal	10%	Stretch Goal	0%
• Achieve a milestone related to a potential in-licensing		• Not Achieved
	100% (additional 42.5% attributable to stretch goals)		87.5%

(1)

Percentages in this column reflect amounts attributable to achievements that relate to each corporate objective and that provide incremental and significant value to the Company for which the Compensation Committee believed management should be incentivized and rewarded.

Our Compensation Committee assessed achievement of the 2025 performance goals following the end of the year, as shown above. Upon the Compensation Committee’s recommendation, in February 2026, the Board approved performance bonuses for each of Dr. Seehra, Mr. Regnante and Ms. Cho in amounts commensurate with the 87.5% performance goal achievement level.

TABLE OF CONTENTS

The table below reflects each named executive officer’s annual performance bonus for 2025:

Named Executive Officer	Total Incentive Amount Paid ($)
Jasbir Seehra, Ph.D.		398,125
Keith Regnante		164,850
Esther Cho, Esq.		161,000
Christopher Rovaldi(1)		—

(1)

Mr. Rovaldi ceased serving as our President and Chief Operating Officer, effective August 18, 2025. As a result, Mr. Rovaldi was not entitled to an annual performance bonus for 2025.

Equity Compensation

We believe that our ability to grant equity awards is a valuable and necessary compensation tool that aligns the financial interests of our executive officers and our stockholders. In addition, we believe that our ability to grant equity awards helps us to attract, retain and motivate executive officers, and fosters an ownership culture, designed to incentivize them to devote their best efforts to the success of our business. As such, our executives generally are awarded an initial grant upon commencement of employment, as well as annual grants thereafter. Additional grants may occur periodically in order to incentivize and reward executives as our Compensation Committee and our Board determine appropriate.

With the exception of equity awards granted during 2025, all equity awards granted to our named executive officers, other than our Chief Executive Officer, had been in the form of stock options that vest based on continuous service with us. Our Compensation Committee believes that stock options are inherently performance-based and automatically link executive pay to stockholder return, as the value realized, if any, from an award of stock options is dependent upon, and directly proportionate to, future appreciation in our stock price. Regardless of the reported value in the Summary Compensation Table, our named executive officers will only receive value from their stock options if the market price of our common stock increases above the market price of our common stock at the time of grant and remains above such price as the stock options continue to vest.

In September 2025, we introduced time-based and performance-vesting RSUs into our Chief Executive Officer’s compensation program, as described below. In 2024, we introduced performance-vesting stock options into our Chief Executive Officer’s long-term incentive package. Our Compensation Committee believes a more diversified long-term incentive program, pursuant to which both performance and time-vesting equity awards are granted to our Chief Executive Officer, better balances our goal of retaining Dr. Seehra, enhancing stockholder value and motivating and incentivizing extraordinary performance.

In addition, in February 2025, our Compensation Committee granted annual equity awards to each of our named executive officers, other than our Chief Executive Officer, in the form of RSU awards, which were subject to time-based vesting. The grant date value of these awards was substantially less than our 2024 annual equity awards.

Each of our named executive officers holds stock options and RSU awards under our 2020 Equity Incentive Plan (the “2020 Plan”), and our Chief Executive Officer holds options under our 2017 Stock Incentive Plan, as amended. Such options and RSU awards were granted subject to the general terms of the applicable plan and the applicable forms of stock option agreement and RSU award agreement, as applicable, thereunder. All options are granted with a per share exercise price equal to the closing price of our common stock on the grant date. All options and RSUs have a maximum term of up to 10 years from the date of grant, subject to earlier expiration following the cessation of an executive officer’s continuous service with us. Option and RSU vesting is subject to acceleration as described below under “Potential Payments upon Termination or Change of Control.”

The specific vesting terms of each named executive officer’s stock options and RSU awards are described below under “Outstanding Equity Awards as of December 31, 2025.” For additional information about our equity compensation plans, please see the section titled “Equity Benefit Plans” below.

TABLE OF CONTENTS

2025 Equity Awards

In February 2025, upon the recommendation of our Compensation Committee, our Board granted RSU awards to each of Mr. Regnante and Mr. Rovaldi, as shown in the table and described below. Additionally, in February 2025, our Compensation Committee granted RSU awards to Ms. Cho, as shown in the table and described below. Each of the RSU awards granted to Mr. Regnante, Ms. Cho and Mr. Rovaldi vests over a two-year period, with 33% of the RSUs vesting on February 17, 2026, an additional 34% of the total number of RSUs vesting on August 15, 2026, and the remaining 33% of the total number of RSUs vesting on February 16, 2027, subject to the executive’s continuous service with us as of each such vesting date.

In September 2025, upon the recommendation of our Compensation Committee, our Board granted RSU awards to Dr. Seehra, as shown in the table and described below. 50% of Dr. Seehra’s 2025 annual equity award vests over a four-year period, with 25% of such time-vesting RSUs vesting on each of February 18, 2026, February 18, 2027, February 18, 2028 and February 18, 2029, subject to Dr. Seehra’s continuous service with us as of each such vesting date. The RSUs are eligible to accelerate under certain circumstances in accordance with the named executive officer’s employment agreement. The remaining 50% of Dr. Seehra’s 2025 annual equity award was granted in the form of a performance-vesting RSU. The number of shares that are eligible to vest (the “eligible shares”) is determined based on the achievement of two rigorous development goals relating to rinvatercept and a preclinical asset, each of which must be achieved on or prior to September 30, 2027. The eligible shares will vest as follows: 50% of such shares will vest on the date of certification of achievement of the performance goals by our Compensation Committee, and the remaining 50% will vest on December 31, 2028, subject to Dr. Seehra’s continuous service with us as of each such vesting date. The RSU is eligible to accelerate under certain circumstances as described below under “Potential Payments upon Termination or Change of Control.” As of the date of this Proxy Statement, the Committee has not determined if either of the performance goals has been met.

In formulating its equity award recommendations, our Compensation Committee used its subjective judgement to determine the amounts and equity award mix it believed were appropriate for each named executive officer, considering, among other factors: market data for the relevant positions (based on award value and percent of company), management of dilution, the retention value of existing holdings, individual performance, role criticality, expected future contribution, disclosure requirements, the Company’s compensation philosophy, proxy advisory firm position and internal equity. Our Compensation Committee will continue to evaluate its long-term incentive strategy and may adjust the award mix or introduce different structures, including performance-based equity, as part of the Company’s overall compensation strategy.

The following table sets forth the RSUs granted to our named executive officers in 2025:

Named Executive Officer

Grant Date

Number of Shares
Underlying RSUs

Jasbir Seehra, Ph.D.

9/3/2025

181,000(1)

Keith Regnante

2/18/2025

44,000

Esther Cho

2/18/2025

44,000

Christopher Rovaldi

2/18/2025(2)

60,000

(1)

50% of Dr. Seehra’s 2025 annual equity award (90,500 shares) was granted in the form of a performance-vesting RSU that vests based on achievement of two rigorous pipeline development objectives. The remaining 50% of his 2025 annual equity award (90,500 shares) was granted in the form of time-vesting RSUs.

(2)

Mr. Rovaldi ceased serving as our President and Chief Operating Officer, effective August 18, 2025. In connection with the cessation of his employment and in exchange for Mr. Rovaldi entering into the Separation Agreement (as described below), an aggregate of 19,800 shares of our common stock subject to his unvested RSUs vested on November 18, 2025, as described below under “Severance and Change in Control Benefits.”

TABLE OF CONTENTS

2024 Chief Executive Officer Equity Awards

As indicated above, in 2024, we introduced performance-vesting stock options into our Chief Executive Officer’s long-term incentive package. Specifically, on February 23, 2024, we granted Dr. Seehra an option to purchase 125,000 shares of common stock, the vesting of which was subject to the achievement of specified performance criteria. 50% of the performance-vesting stock options was eligible to vest based on the achievement of a performance goal relating to generating data for our cibotercept (KER-012) program to advance to a registrational trial, and the remaining 50% was eligible to vest based on the achievement of a performance goal relating to generating data for our rinvatercept program to advance to a Phase 2 clinical trial, in each case, on or prior to December 31, 2025. On January 7, 2026, the Compensation Committee determined that the performance goal relating to our rinvatercept program had been met, resulting in the immediate vesting of 31,250 shares and the vesting of 31,250 shares on December 31, 2026, subject to Dr. Seehra’s continuous service through such date. The Compensation Committee also determined that the performance goal related to our cibotercept program had not been met, resulting in the forfeiture of 62,500 shares for no consideration.

Preview of 2026 Equity Awards

In February 2026, we granted annual equity awards to each of Dr. Seehra, Mr. Regnante and Ms. Cho in the form of stock options. 31.5% of Dr. Seehra’s 2026 annual equity award was granted in the form of a stock option that vests in one-fourth increments upon the closing price of our common stock equaling or exceeding 125%, 150%, 175% and 200%, respectively, of the exercise price for 30 calendar days between February 24, 2026 and February 24, 2031. The remaining 68.5% of his 2026 annual equity award is in the form of time-vesting stock options. Our Compensation Committee believes a more diversified long-term incentive program, pursuant to which both performance and time-vesting stock options are granted to our Chief Executive Officer, better balances our goal of retaining Dr. Seehra, enhancing stockholder value and motivating and incentivizing extraordinary performance.

Other Features of Our Compensation Program

Employment Arrangements

We have entered into offer letter and employment agreements with each of our named executive officers. These agreements provide for base salaries and incentive compensation, and each component reflects the scope of each named executive officer’s anticipated responsibilities and the individual experience they bring to us. The employment of each of our named executive officers is “at will” and may be terminated at any time. In addition, each of our named executive officers has executed a form of our standard proprietary information and inventions agreement.

Severance and Change in Control Benefits

Regardless of the manner in which a named executive officer’s service terminates, each named executive officer is entitled to receive amounts earned during his term of service, including unpaid salary and unused vacation. Pursuant to the offer letter and employment agreements entered into with each of our named executive officers, our named executive officers are entitled to certain severance benefits upon an involuntary termination without cause (and not due to death or disability) or upon a resignation for good reason, either alone or immediately before or within 12 months following a change in control of our Company, subject to specific requirements, including signing and not revoking a separation agreement and release of claims. Cause, change in control, disability and good reason are defined in the agreements. The Compensation Committee believes that these severance benefits are necessary to provide stability among our named executive officers, to focus our named executive officers on our business operations and to encourage continued attention and dedication to duties without distractions in connection with a potential change in control transaction or period of uncertainty.

In August 2025, we announced a strategic realignment of the Company designed to reallocate resources towards the development of rinvatercept, our key clinical program. In connection with this strategic realignment, Mr. Rovaldi ceased serving as our President and Chief Operating Officer, effective August 18, 2025. In connection with the cessation of his employment, Mr. Rovaldi has entered into a separation and

TABLE OF CONTENTS

release agreement with the Company, effective August 18, 2025 (the “Separation Agreement”). Pursuant to the Separation Agreement, Mr. Rovaldi was obligated to provide up to 20 hours of consulting services to us for the three-month period following August 18, 2025 (the “Separation Date”) until November 18, 2025 (the “Consulting Period”). As consideration for any consulting services in excess of 20 hours during the Consulting Period, we were obligated to pay Mr. Rovaldi an hourly fee of $425.00. Mr. Rovaldi’s consulting services were limited to 20 hours or less and as a result the hourly fee was not payable. In addition, we will provide Mr. Rovaldi with (a) cash severance equivalent to nine months of Mr. Rovaldi’s base salary in effect as of the Separation Date, (b) reimbursement of COBRA healthcare premium costs for the same level of coverage he had during employment until the earlier of (i) nine months, (ii) the expiration of Mr. Rovaldi’s eligibility for the continuation coverage, or (iii) the date Mr. Rovaldi becomes eligible for substantially equivalent healthcare coverage through another source, (c) acceleration of vesting of an aggregate of 19,800 shares of our common stock subject to his unvested RSUs, effective upon the expiration of the Consulting Period and (d) reimbursement of outplacement services used by Mr. Rovaldi (up to $10,000) for a period not to exceed one year following the Separation Date. The Separation Agreement also contains confidentiality, non-competition, non-disparagement and non-solicitation covenants and a release of claims by Mr. Rovaldi.

For a detailed description of the severance provisions contained in our named executive officers’ offer letter and employment agreements, see “Potential Payments upon Termination or Change of Control” below.

401(k) Plan

Our named executive officers are eligible to participate in a 40l(k) plan intended to qualify as a tax-qualified plan under Section 401 of the Internal Revenue Code of 1986, as amended (the “Code”), with the 40l(k) plan’s related trust intended to be tax exempt under Section 501(a) of the Code. The 40l(k) plan provides that each participant may contribute up to the lesser of 100% of his or her compensation or the statutory limit, which was $23,500 for calendar year 2025 (subject to catch-up contributions for individuals aged 50 and over). For the 2025 calendar year, we made matching contributions equal to 100% of a participant’s eligible compensation up to the first 4% of such person’s elected deferral. Matching contributions are immediately fully vested. Employees’ pre-tax contributions are allocated to each participant’s individual account and are then invested in selected investment alternatives according to the participant’s directions. Employees are immediately and fully vested in their contributions. As a tax-qualified retirement plan, contributions to the 40l(k) plan and earnings on those contributions are not taxable to the employees until distributed from the 40l(k) plan.

Health/Welfare Plans

Our named executive officers are eligible to participate in all of our benefit plans, such as the 401(k) plan (see the section above titled “401(k) Plan” above), medical, dental, vision, disability and life insurance, in each case generally on the same basis as other employees. We do not currently have qualified or nonqualified defined benefit plans or deferred compensation plans, nor do we offer pension or other retirement benefits, other than our 401(k) plan. Our Compensation Committee may elect to adopt such plans in the future if it determines that doing so is in our best interests.

Perquisites and Other Benefits

We typically do not offer perquisites or personal benefits to our executive officers, including the named executive officers, except in situations where we believe it is appropriate to assist an individual in the performance of such individual’s duties, to make our executive officers more efficient and effective and for recruitment and retention purposes. In 2025, we provided Dr. Seehra with a reimbursement of $1,799 for cell phone expenses.

In the future, we may provide perquisites or other personal benefits in limited circumstances. All future practices with respect to perquisites or other personal benefits will be approved and subject to periodic review by our Compensation Committee.

Tax and Accounting Considerations

As a general matter, our Compensation Committee reviews and considers the various tax and accounting implications of compensation programs we utilize.

TABLE OF CONTENTS

Code Section 162(m)

Under Section 162(m) of the Internal Revenue Code of 1986, as amended (the “Code”) (“Section 162(m)”), compensation paid to any of the publicly held corporation’s “covered employees” that exceeds $1 million per taxable year for any covered employee is generally non-deductible for tax purposes. Although our Compensation Committee will continue to consider tax implications as one factor in determining executive compensation, our Compensation Committee also looks at other factors in making its decisions and recommendations and retains the flexibility to provide compensation for our named executive officers in a manner consistent with the goals of the Company’s executive compensation program and the best interests of the Company, which may include compensation that is not deductible by the Company due to the deduction limit under Section 162(m).

Code Section 409A

Section 409A of the Code (“Section 409A”) requires that “nonqualified deferred compensation” be deferred and paid under plans or arrangements that satisfy the requirements of the statute with respect to the timing of deferral elections, timing of payments and certain other matters. Failure to satisfy these requirements can expose employees and other service providers to accelerated income tax liabilities, penalty taxes and interest on their vested compensation under such plans. Accordingly, as a general matter, it is our intention to design and administer our compensation and benefits plans and arrangements for all of our employees and other service providers, including our named executive officers, so that they are either exempt from, or satisfy the requirements of, Section 409A.

Code Section 280G

Section 280G of the Code (“Section 280G”) disallows a tax deduction with respect to excess parachute payments to certain executives of companies which undergo a change of control. In addition, Section 4999 of the Code imposes a 20% excise tax on the individual with respect to the excess parachute payment. Parachute payments are compensation linked to or triggered by a change of control and may include, but are not limited to, bonus payments, severance payments, certain fringe benefits, and payments and acceleration of vesting from long-term incentive plans including stock options, restricted stock and other equity-based compensation. Excess parachute payments are parachute payments that exceed a threshold determined under Section 280G based on the executive’s prior compensation. In recommending or approving the compensation arrangements for our named executive officers, our Compensation Committee considers all elements of the cost to us of providing such compensation, including the potential impact of Section 280G. However, our Compensation Committee may, in its judgment, authorize compensation arrangements that could give rise to loss of deductibility under Section 280G and the imposition of excise taxes under Section 4999 when it believes that such arrangements are appropriate to attract and retain executive talent. None of our named executive officers is entitled to any Section 280G gross-up.

Accounting for Stock-Based Compensation

We follow the Financial Accounting Standards Board’s Accounting Standards Codification Topic 718 (“ASC Topic 718”) for our stock-based compensation awards. ASC Topic 718 requires companies to calculate the grant date “fair value” of their stock-based awards using a variety of assumptions. ASC Topic 718 also requires companies to recognize the compensation cost of their stock-based awards in their income statements over the period that an employee is required to render service in exchange for the award. Grants of stock options under our equity incentive award plans are accounted for under ASC Topic 718. Our Compensation Committee considers the accounting implications of significant compensation decisions, especially in connection with decisions that relate to our equity award programs. As accounting standards change, we may revise certain programs to appropriately align accounting expenses of our equity awards with our overall executive compensation philosophy and objectives.

Other Compensation Policies and Practices

Equity Grant Timing

From time to time, the Company grants stock options to its employees, including our named executive officers. Our historical practice has been to grant annual equity awards to all employees, including our named

TABLE OF CONTENTS

executive officers, at the beginning of the year (typically in February) and new hire or promotion grants around the commencement of employment or promotion date or as otherwise determined appropriate by the Compensation Committee. In January 2025, our Compensation Committee adopted an equity award grant policy, which creates a framework for a consistent process for granting equity awards under the 2020 Plan to all employees, including to our named executive officers. Also, non-employee directors receive automatic grants of initial and annual stock option awards, at the time of a director’s initial appointment or election to the board and at the time of each annual meeting of the Company’s stockholders, respectively, pursuant to the Non-Employee Director Compensation Policy, as further described under the heading, “Non-Employee Director Compensation — Non-Employee Director Compensation Policy” below. Option grants are made on the regular, predetermined grant dates pursuant to the equity grant policy (and previously, the equity grant delegation policy) and the Non-Employee Director Compensation Policy. The equity grant policy provides for an adjustment of such predetermined grant date if it falls within a designed blackout window relating to our release of financial or certain material non-public information (“MNPI”) about the Company. The Company has not granted equity awards in anticipation of the release of MNPI and we have not timed the release of MNPI based on equity award grant dates or for the purposes of affecting the value of executive compensation. We have no information to disclose pursuant to Item 402(x)(2) of Regulation S-K. Our Compensation Committee will continue to evaluate our equity grant policies as we continue to evolve and grow as a public company.

Compensation Recovery (“Clawback”) Policy

On October 5, 2023, we adopted our Incentive Compensation Recoupment Policy, which complies with the listing standards adopted by Nasdaq that implement the related SEC rules under the Dodd-Frank Wall Street Reform and Consumer Protection Act.

In addition to the above, as a public company, if we are required to restate our financial results due to our material noncompliance with any financial reporting requirements under the federal securities laws as a result of misconduct, our Chief Executive Officer and Chief Financial Officer may be legally required to reimburse us for any bonus or other incentive-based or equity-based compensation they receive in accordance with the provisions of Section 304 of the Sarbanes-Oxley Act of 2002.

Stock Ownership Requirements

To promote a focus on long-term growth and to align the interests of the Company’s executive officers and directors (the “covered individuals”) with those of our stockholders, the Board adopted stock ownership guidelines, effective May 2025, requiring certain minimum ownership levels of our common stock, based on position:

Position			Requirement
Chief Executive Officer			3x base salary
Other executive officers			1x base salary
Directors			2x annual board retainer

The guidelines must be achieved by each covered individual by the end of the calendar year in which occurs the date that is five years after the later of (1) the effective date of the guidelines and (2) the date the individual became a covered individual. In the event of a 20% or greater change in base salary or annual board retainer, as applicable, the covered individual will have three years from the end of the calendar year in which occurs the date of the change to acquire any additional shares or RSUs needed to meet the guidelines. For purposes of these guidelines, common stock ownership includes (i) shares of common stock individually owned or owned together with immediate family members, (ii) shares held in trust for the benefit of the covered individual or for the benefit of an immediate family member of such covered individual, (iii) shares owned by an entity for which the covered individual serves as a partner or is otherwise materially affiliated with (as determined in the sole discretion of the Board), if such entity beneficially owns 5% or more of our outstanding shares (as determined in accordance with applicable SEC rules and regulations), (iv) vested shares under any deferred compensation plan, (v) time-based RSUs (whether or not vested), and (vi) vested performance-based RSUs, but does not include unexercised stock options or unvested performance-based RSUs.

TABLE OF CONTENTS

Our covered individuals are making progress toward these guidelines, in accordance with the five-year phase in period.

Hedging and Pledging of Securities

We believe it is improper and inappropriate for any person associated with us to engage in short-term or speculative transactions involving our securities. Our directors, officers and employees are, therefore, prohibited from engaging in short sales, transactions in put or call options, hedging transactions, margin accounts, pledges or other inherently speculative transactions with respect to our common stock at any time.

Summary Compensation Table

The following table shows, for the years ended December 31, 2025 and 2024, compensation awarded to, paid to or earned by our NEOs:

Name and Principal Position	Year		Salary ($)		Stock Awards ($)(1)		Option Awards ($)(1)		Non-Equity Incentive Plan Compensation(2)		All Other Compensation ($)		Total ($)
Jasbir Seehra, Ph.D. President and Chief Executive Officer		2025		700,000		1,426,280		—		398,125		15,799(3)		2,540,204
Jasbir Seehra, Ph.D. President and Chief Executive Officer		2024		699,039		—		5,104,488		455,000		14,666		6,273,192
Keith Regnante Chief Financial Officer		2025		470,382		464,640		—		164,850		14,000(4)		1,113,872
Keith Regnante Chief Financial Officer		2024		447,799		—		1,633,436		197,142		13,800		2,292,177
Esther Cho, Esq.(5) Chief Legal Officer		2025		459,192		464,640		—		161,000		14,000(4)		1,098,832
Christopher Rovaldi(6) Former President and Chief Operating Officer		2025		578,923		871,200		—		—		25,990(7)		1,476,114
		2024		539,231		—		6,125,385		297,000		13,800		6,975,416

(1)

This column reflects the aggregate grant date fair value of all time-vesting and performance-vesting RSU and option awards granted during the indicated year measured pursuant to ASC Topic 718, the basis for computing stock-based compensation in our audited consolidated financial statements, excluding the effect of estimated forfeitures. This calculation assumes that the NEO will perform the requisite service for the award to vest in full as required by SEC rules. The performance-vesting RSU award granted to Dr. Seehra in 2025 are eligible to vest contingent upon the achievement of two rigorous development goals, as further described under “Executive Compensation — Elements of Our 2025 Executive Compensation Program — Equity Compensation” in this Proxy Statement. As such, the grant date fair value of such awards is based on the probable outcome of the performance conditions as of the grant date. The maximum potential value of such awards (assuming the highest level of performance achievement) is $1,426,280. The assumptions we used in valuing options and RSU awards are described in the notes to our audited consolidated financial statements included in our Annual Report on Form 10-K for the year ended December 31, 2025. These amounts do not reflect the actual economic value that will be realized by the NEO upon vesting of the stock options or RSU awards, the exercise of the stock options, or the sale of the common stock underlying such stock options and RSU awards.

(2)

This column reflects the amount of performance-based incentive compensation earned by our NEOs for the periods presented. For a description of the Company’s annual performance-based bonus program for 2025, see “Executive Compensation — Elements of Our 2025 Executive Compensation Program — Annual Cash Performance Bonus” in this Proxy Statement.

(3)

Represents (i) a match of contributions to the Company’s 401(k) savings plan in the amount of $14,000 and (ii) reimbursed cell phone expenses in the amount of $1,799.

(4)

Represents a match of contributions to the Company’s 401(k) savings plan.

(5)

Ms. Cho was not an NEO for 2024, nor have we previously reported her compensation for 2024. Accordingly, we have excluded Ms. Cho’s compensation for 2024.

(6)

Mr. Rovaldi ceased his employment with the Company, effective August 18, 2025.

TABLE OF CONTENTS

(7)

Represents (i) a match of contributions to the Company’s 401(k) savings plan in the amount of $14,000 and (ii) accrued vacation in the amount of $11,990 paid to Mr. Rovaldi in connection with his cessation of employment in 2025.

Outstanding Equity Awards as of December 31, 2025

The following table sets forth certain information about equity awards granted to our NEOs that remained outstanding as of December 31, 2025.

					Option Awards(1)										Stock Awards
Name	Grant Date		Vesting Commencement Date		Number of Securities Underlying Unexercised Options (#) Exercisable		Number of Securities Underlying Unexercised Options (#) Unexercisable		Equity Incentive Plan Awards: Number of Securities Underlying Unexercised Unearned Options (#)		Option Exercise Price Per Share ($)		Option Expiration Date		Number of Shares or Units of Stock That Have Not Vested (#)		Market Value of Shares of Units of Stock That Have Not Vested ($)(2)		Equity Incentive Plan Awards: Number of Unearned Shares, Units or Other Rights that Have not Vested (#)		Equity Incentive Plan Awards: Market or Payout Value of Unearned Shares, Units or Other Rights that Have not Vested ($)(2)
Jasbir Seehra, Ph.D.		9/3/2025		2/18/2025(3)		—		—		—		—		—		90,500		1,842,580		—		—
		9/3/2025		9/3/2025(4)		—		—		—		—		—		—		—		90,500		1,842,580
		2/23/2024		2/23/2024(5)		—		—		125,000		63.61		2/22/2034		—		—		—		—
		2/13/2024		2/13/2024(6)		54,687		70,313		—		56.18		2/12/2034		—		—		—		—
		2/16/2023		2/16/2023(6)		137,500		62,500		—		54.38		2/15/2033		—		—		—		—
		1/21/2022		1/19/2022(6)		154,687		10,313		—		46.30		1/20/2032		—		—		—		—
		1/10/2021		1/7/2021(6)		127,200		—		—		70.93		1/9/2031		—		—		—		—
		4/7/2020		3/1/2020(6)		696,569		—		—		16.00		4/6/2030		—		—		—		—
		6/19/2019		12/1/2018(6)		45,087		—		—		0.48		6/18/2029		—		—		—		—
		3/26/2018		12/18/2017(7)		8,822		—		—		0.30		3/25/2028		—		—		—		—
		3/26/2018		12/18/2017(8)		252,444		—		—		0.30		3/25/2028		—		—		—		—
Keith Regnante		2/18/2025		2/18/2025(9)		—		—		—		—		—		44,000		895,840		—		—
		2/13/2024		2/13/2024(6)		17,500		22,500		—		56.18		2/12/2034		—		—		—		—
		2/16/2023		2/16/2023(6)		27,500		12,500		—		54.38		2/15/2033		—		—		—		—
		1/21/2022		1/19/2022(6)		46,875		3,125		—		46.30		1/20/2032		—		—		—		—
		1/10/2021		1/7/2021(6)		49,150		—		—		70.93		1/9/2031		—		—		—		—
		4/7/2020		3/1/2020(6)		53,622		—		—		16.00		4/6/2030		—		—		—		—
		4/7/2020		2/24/2020(6)		18,430		—		—		16.00		4/6/2030		—		—		—		—
Esther Cho, Esq.		2/18/2025		2/18/2025(9)		—		—		—		—		—		44,000		895,840
		2/13/2024		2/13/2024(6)		21,875		28,125		—		56.18		2/12/2034		—		—		—		—
		2/16/2023		2/16/2023(6)		34,375		15,625		—		54.38		2/15/2033		—		—		—		—
		1/21/2022		1/19/2022(6)		23,437		1,563		—		46.30		1/20/2032		—		—		—		—
		1/10/2021		1/7/2021(6)		20,000		—		—		70.93		1/9/2031		—		—		—		—
		5/4/2020		4/22/2020(6)		20,968		—		—		29.02		5/4/2030		—		—		—		—
Christopher Rovaldi		—		—		—		—		—		—		—		—		—		—		—

(1)

All of the option awards listed in the table above granted prior to the pricing of our IPO on April 7, 2020 were granted under our 2017 Plan and all of the option awards granted on or after the pricing of our IPO were granted under our 2020 Plan.

(2)

Calculated based on the closing price per share of our common stock on December 31, 2025, which was $20.36.

(3)

The RSU award vests as follows: 25% of the shares shall vest on each of the first, second, third and fourth anniversaries of the vesting commencement date, subject to continued service through each such applicable vesting date.

(4)

The RSU award is eligible to vest contingent upon the achievement of two rigorous development goals, as further described under “Executive Compensation — Elements of Our 2025 Executive Compensation Program — Equity Compensation” in this Proxy Statement.

TABLE OF CONTENTS

(5)

The option award is eligible to vest contingent upon the achievement of two rigorous development goals, as further described under “Executive Compensation — Elements of Our 2025 Executive Compensation Program — Equity Compensation — 2024 Chief Executive Officer Equity Awards” in this Proxy Statement.

(6)

Each option award vests as follows: 25% of the shares subject to the option vest on the first anniversary of the vesting commencement date and 6.25% of the shares subject to the option vest at the end of each successive three (3) month period following the first anniversary of the vesting commencement date until the fourth anniversary of the vesting commencement date, subject to continued service through each such applicable vesting date.

(7)

Each option award vests as follows: 8.33% of the shares subject to the option vest at the end of each successive three (3) month period following the vesting commencement date until the third anniversary of the vesting commencement date, subject to continued service through each such applicable vesting date.

(8)

Each option award vests as follows: 50% of the shares subject to the option are fully vested and 6.25% of the shares subject to the option vest at the end of each successive three (3) month period following the vesting commencement date until the second anniversary of the vesting commencement date, subject to continued service through each such applicable vesting date.

(9)

Each RSU award vests as follows: 33% of the shares shall vest on February 17, 2026, an additional 34% of the total number of shares shall vest on August 15, 2026, and the remaining 33% of the total number of shares shall vest on February 16, 2027, subject to continued service through each such applicable vesting date.

Pension Benefits

We do not have any qualified or non-qualified defined benefit plans.

Nonqualified Deferred Compensation

We do not have any non-qualified defined contribution plans or other deferred compensation plans.

Employment Arrangements

We have employment agreements with each of our NEOs. The material terms of each of these agreements are described below. These agreements provide for base salaries and incentive compensation, and each component reflects the scope of each NEO’s anticipated responsibilities and the individual experience they bring to our Company. The employment of each of our NEOs is “at will” and may be terminated at any time. In addition, each of our NEOs has executed a form of our standard proprietary information and inventions agreement.

Jasbir Seehra, Ph.D. We entered into an offer letter agreement with Dr. Seehra in December 2015, which was amended and restated by an employment agreement entered into in March 2020 and effective on April 13, 2020. Pursuant to his April 2020 agreement, Dr. Seehra is entitled to an annual base salary, an annual performance bonus and certain severance benefits, as described below under “— Potential Payments upon Termination or Change of Control.” Dr. Seehra is eligible to participate in the employee benefit plans generally available to our employees, and is subject to customary confidentiality covenants, as well as a non-competition and non-solicitation covenant for a period of 12 months following termination of his employment.

Keith Regnante. We entered into an offer letter agreement with Mr. Regnante in February 2020, which was amended and restated by an employment agreement entered into in March 2020 and effective on April 13, 2020, and further amended on January 1, 2022. Pursuant to his April 2020 agreement, as amended, Mr. Regnante is entitled to an annual base salary, an annual performance bonus and certain severance benefits, as described below under “— Potential Payments upon Termination or Change of Control.” Mr. Regnante is eligible to participate in the employee benefit plans generally available to our employees, and is subject to customary confidentiality covenants, as well as a non-competition and non-solicitation covenant for a period of 12 months following his termination of employment.

TABLE OF CONTENTS

Esther Cho. We entered an employment agreement with Ms. Cho in August 2025, which was effective on August 6, 2025 and amended on February 24, 2026. Pursuant to her agreement, Ms. Cho is entitled to an annual base salary, an annual performance bonus and certain severance benefits, as described below under “— Potential Payments upon Termination or Change of Control.” Ms. Cho is eligible to participate in the employee benefit plans generally available to our employees, and is subject to customary confidentiality covenants, as well as a non-competition and non-solicitation covenant for a period of 12 months following her termination of employment.

Christopher Rovaldi. We entered an employment agreement with Mr. Rovaldi in January 2022, which was effective on February 1, 2022. Mr. Rovaldi ceased his employment with us, effective August 18, 2025.

Additional Benefits

Our named executive officers are eligible to participate in our benefit plans, such as the 401(k) plan, generally on the same basis as other employees, as described in “Executive Compensation — Other Features of Our Compensation Program.”

Potential Payments upon Termination or Change of Control

Christopher Rovaldi. Mr. Rovaldi ceased his employment with us, effective August 18, 2025. In connection with the cessation of his employment, Mr. Rovaldi entered into the Separation Agreement. Pursuant to the Separation Agreement, Mr. Rovaldi provided up to 20 hours of consulting services to the Company for the Consulting Period. As consideration for any consulting services in excess of 20 hours during the Consulting Period, we were obligated to pay Mr. Rovaldi an hourly fee of $425.00. Mr. Rovaldi’s consulting services were limited to 20 hours or less and as a result the hourly fee was not payable. In addition, we provided Mr. Rovaldi with (a) cash severance equivalent to nine months of Mr. Rovaldi’s base salary in effect as of the Separation Date, (b) reimbursement of COBRA healthcare premium costs for the same level of coverage he had during employment until the earlier of (i) nine months, (ii) the expiration of Mr. Rovaldi’s eligibility for the continuation coverage, or (iii) the date Mr. Rovaldi becomes eligible for substantially equivalent healthcare coverage through another source, (c) acceleration of vesting of an aggregate of 19,800 shares of our common stock subject to his unvested RSUs, effective upon the expiration of the Consulting Period and (d) reimbursement of outplacement services used by Mr. Rovaldi (up to $10,000) for a period not to exceed one year following the Separation Date. The Separation Agreement also contains confidentiality, non-competition, non-disparagement and non-solicitation covenants and a release of claims by Mr. Rovaldi.

Jasbir Seehra, Ph.D., Keith Regnante and Ms. Cho. Regardless of the manner in which an NEO’s service terminates, each NEO is entitled to receive amounts earned during his or her term of service, including unpaid salary and unused vacation. Pursuant to the employment agreements entered into with each of our NEOs, our NEOs are entitled to certain severance benefits, subject to specific requirements, including signing and not revoking a separation agreement and release of claims. Cause, change of control, disability and good reason are defined in the agreements.

If the executive is terminated by the Company involuntarily without cause (and not due to death or disability) or the executive resigns for good reason, in each case, not in connection with a change of control then:

•

With respect to Dr. Seehra, he will be entitled to cash severance equal to continued base salary payments for 12 months; continued vesting of the executive’s options for a period of 12 months; a lump sum payment equal to 100% of the executive’s target bonus pro-rated for the year of termination, only if the executive is terminated on or after July 1 of the calendar year; and payment of COBRA premiums for up to 12 months.

•

With respect to Mr. Regnante and Ms. Cho, the executive will be entitled to cash severance equal to continued base salary payments for nine months and payment of COBRA premiums for up to nine months.

If immediately before or within 12 months following a change of control, the executive is terminated by the Company or successor involuntarily without cause (and not due to death or disability) or the executive

TABLE OF CONTENTS

resigns for good reason, the executive shall be entitled to cash severance equal to continued base salary payments for 18 months for Dr. Seehra or for 12 months for our other NEOs; acceleration of all of the executive’s unvested and outstanding equity awards; a lump sum payment equal to 100% of the executive’s target bonus for the year of termination; and payment of COBRA premiums for up to 18 months for Dr. Seehra or up to 12 months for our other NEOs.

Jasbir Seehra, Ph.D. As further described under “Executive Compensation — Elements of Our 2025 Executive Compensation Program — Equity Compensation” in this Proxy Statement, Dr. Seehra was granted a performance-vesting option in February 2024 and performance-vesting RSUs in September 2025. The option and RSUs are subject to acceleration under specified conditions. For purposes of both equity awards, involuntary termination refers to termination of continuous service without cause (and not due to death or disability) or resignation for good reason. Cause, disability and good reason are defined in Dr. Seehra’s employment agreement. The change in control period refers to the time period beginning immediately before and terminating two years following a change in control (as defined in the 2020 Plan).

•

In the event of a change in control prior to vesting of any portion of the applicable equity award and during Dr. Seehra’s continuous service, if the surviving or acquiring corporation does not assume, continue or substitute the applicable equity award, the applicable equity award will accelerate in full.

•

In the event of Dr. Seehra’s involuntary termination outside of the change in control period and prior to vesting of any portion of the applicable equity award, the applicable equity award will remain outstanding and eligible to vest for 12 months, after which it will terminate (subject to satisfaction of a release condition).

•

In the event of Dr. Seehra’s involuntary termination during the change in control period and prior to vesting of any portion of the applicable equity award, the applicable equity award will accelerate in full (subject to satisfaction of a release condition).

•

After the first vesting tranche, if either (i) a change in control occurs during Dr. Seehra’s continuous service or (ii) Dr. Seehra experiences an involuntary termination, the applicable equity award will be treated consistently with other time-vesting equity awards, as applicable, in accordance with the 2020 Plan and Dr. Seehra’s employment agreement.

Equity Benefit Plans

Since the completion of our IPO in April 2020, we grant equity awards to employees, including our NEOs, under our 2020 Plan. Prior to our IPO, we granted equity awards to our employees, including our NEOs, under our 2017 Plan. Our Board has delegated authority to our Compensation Committee to administer the terms of our 2020 Plan and 2017 Plan, which are together referred to as the Equity Plans. The Equity Plans’ provisions regarding treatment of awards upon a termination, significant corporate transaction or change in control transaction are summarized below.

Under the terms of the Equity Plans and the form of award agreements thereunder, stock awards generally cease vesting and terminate upon the holder’s termination of service with us and options generally remain exercisable for a short period of time following the holder’s termination of service with us (generally three months, with longer periods upon terminations for death or disability), but in no event beyond the expiration of the option’s original term.

In the event of certain specified significant corporate transactions, any stock awards outstanding under the 2020 Plan may be assumed, continued or substituted for by any surviving or acquiring corporation (or its parent). If the surviving or acquiring corporation (or its parent) does not assume, continue or substitute for such stock awards, then (i) with respect to stock awards that are held by participants whose continuous service has not terminated prior to the corporate transaction, or current participants, the vesting (and exercisability, if applicable) of such stock awards will be accelerated in full (meaning at 100% of target level for certain performance awards, unless the administrator or relevant award agreement provides otherwise) to a date prior to the corporate transaction, and such stock awards will terminate if not exercised (if applicable) at or prior to the corporate transaction, and (ii) any such stock awards that are held by persons other than current participants will terminate if not exercised (if applicable) prior to the corporate transaction. In the

TABLE OF CONTENTS

event a stock award will terminate if not exercised prior to the corporate transaction, the plan administrator may provide that the holder of such stock award may not exercise such stock award but instead will receive a payment, as described in the 2020 Plan.

Under our 2017 Plan, in the event of a merger, consolidation, share exchange transaction or liquidation or dissolution of the Company, the plan administrator has the discretion to take a variety of actions with respect to outstanding stock awards, including arranging for their assumption or substitution; accelerated vesting; termination in exchange for payment or for no payment; and/or conversion into the right to receive liquidation proceeds.

We are not obligated to treat all stock awards under the 2020 Plan or 2017 Plan, even those that are of the same type, in the same manner. Additionally, we may provide for additional vesting and exercisability or settlement in the event of certain types of change in control transactions in an individual award agreement or in any other written agreement between us and a participant. Our NEOs’ equity acceleration benefits are described in the section above entitled “Potential Payments upon Termination or Change in Control.”

Pursuant to our 2020 Plan, the maximum number of shares of our common stock subject to awards granted under our 2020 Plan or otherwise to any of our non-employee directors with respect to any period commencing on the date of our annual meeting of stockholders for a particular year and ending on the day immediately prior to the date of our annual meeting of stockholders for the next subsequent year, or the annual period, taken together with any cash fees paid by us to such non-employee director with respect to such annual period for serving on our Board, will not exceed $500,000 in total value, or, with respect to such annual period in which a non-employee director is first appointed or elected to our Board, $700,000 in total value (in each case calculating the value of any such stock awards to be based on their grant date fair market value for financial reporting purposes).

Please refer to the plan documents filed as exhibits to our Annual Report on Form 10-K for the year ended December 31, 2025 filed with the SEC on March 4, 2026 for a complete description of the terms of such plans.

Employee Stock Purchase Plan

In connection with our IPO, we adopted our 2020 Employee Stock Purchase Plan (“ESPP”). The ESPP is intended to qualify as an “employee stock purchase plan” within the meaning of Section 423 of the Code. Under our ESPP, our employees, including our NEOs, have the opportunity to purchase shares of our common stock at a discount to market value. Pursuant to the ESPP, each eligible employee, including each eligible NEO, may allocate up to 15% of the participant’s earnings to purchase our stock at a price per share that is at least the lesser of (i) 85% of the fair market value of a share of our common stock on the first trading date of an offering or (ii) 85% of the fair market value of a share of our common stock on the date of purchase, subject to the terms of the ESPP and to the Code.

Please refer to the plan document filed as an exhibit to our Annual Report on Form 10-K for the year ended December 31, 2025 filed with the SEC on March 4, 2026 for a complete description of the terms of such plan.

Rule 10b5-1 Sales Plans

Our directors and executive officers have adopted and may adopt written plans, known as Rule 10b5-1 plans, in which they will contract with a broker to buy or sell shares of our common stock on a periodic basis. Under a Rule 10b5-1 plan, a broker executes trades pursuant to parameters established by the director or officer when entering into the plan, without further direction from the director or officer. It is also possible that the director or officer could amend or terminate the plan when not in possession of MNPI. In addition, our directors and executive officers may buy or sell additional shares outside of a Rule 10b5-1 plan when they are not in possession of MNPI.

TABLE OF CONTENTS

ITEM 402(V) PAY VERSUS PERFORMANCE

The disclosure included in this section is prescribed by SEC rules and does not necessarily align with how the Company or the Compensation Committee view the link between the Company’s performance and NEO pay. For additional information about our compensation and pay-for-performance philosophy and how we align executive compensation with Company performance, refer to “Executive Compensation” in this Proxy Statement, beginning on page 28.

Required Tabular Disclosure of Pay Versus Performance

The amounts set forth below under the headings “Compensation Actually Paid to PEO” and “Average Compensation Actually Paid to Non-PEO NEOs” have been calculated in a manner consistent with Item 402(v) of Regulation S-K. Use of the term “compensation actually paid” (“CAP”) is required by the SEC’s rules and as a result of the calculation methodology required by the SEC, such amounts differ from compensation actually received by the individuals and the compensation decisions described in “Executive Compensation.”

In 2025, the Company did not use any “financial performance measures” as defined in Item 402(v) of Regulation S-K to link compensation paid to the NEOs. Accordingly, we have omitted the tabular list of financial performance measures and the table below does not include a column for “Company-Selected Measure” as defined in Item 402(v) of Regulation S-K. Our Chief Executive Officer is our principal executive officer and is referred to as “PEO” in the headers to the following tables.

Year	Summary Compensation Table Total for PEO(1)(2) ($)		Compensation Actually Paid to PEO(1)(3) ($)		Average Summary Compensation Table Total for Non-PEO NEOs(1)(2) ($)		Average Compensation Actually Paid to Non-PEO NEOs(1)(3) ($)		Value of Initial Fixed $100 Investment Based On:		Net Income (Loss) (in thousands)(5) ($)
Year	Summary Compensation Table Total for PEO(1)(2) ($)		Compensation Actually Paid to PEO(1)(3) ($)						Total Shareholder Return(4) ($)		Net Income (Loss) (in thousands)(5) ($)
2025		2,540,204		3,710,551		1,229,606		684,822		28.86		87,014
2024		6,273,192		2,696,954		4,167,434		709,909		22.44		(187,353)
2023		8,932,076		3,436,404		3,043,725		1,669,962		56.37		(152,992)

(1)

NEOs included in these columns reflect the following individuals:

Year	PEO	Non-PEO NEOs
2025	Jasbir Seehra	Keith Regnante, Esther Cho, Christopher Rovaldi
2024	Jasbir Seehra	Keith Regnante, Simon Cooper, Christopher Rovaldi, Yung Chyung
2023	Jasbir Seehra	Keith Regnante, Simon Cooper, Christopher Rovaldi

(2)

The Summary Compensation Table totals reflected are as reported for the PEO and the average of the non-PEO NEOs for each of 2025, 2024 and 2023.

(3)

Represents the amount of CAP to Dr. Seehra and average amount of CAP to our non-PEO NEOs, respectively, as computed in accordance with Item 402(v) of Regulation S-K. The dollar amounts do not reflect the actual amount of compensation earned by or paid to our NEOs during the applicable year. In accordance with the requirements of Item 402(v) of Regulation S-K, the following adjustments were made to total compensation for each year to determine CAP:

TABLE OF CONTENTS

Year	NEOs	Summary Compensation Table (“SCT”) Total Compensation ($)		Deduct: Grant Date Fair Value of the “StockAwards” and “Option Awards” Columns in the SCT for Applicable Year ($)*		Add: Fair Value at Applicable Year End of Awards Granted During Applicable Year that Remain Unvested as of Applicable Year End ($)*		Add: Change in Fair Value from the end of the Prior Year to the End of the Applicable Year of Awards Granted During Prior Year that Were Outstanding and Unvested as of Applicable Year End ($)*		Add: Fair Value as of the Vesting Date of Awards that were Granted and Vested During the Applicable Year ($)		Add: Change in Fair Value as of the Vesting Date of Prior Years’ Awards that Vested During the Applicable Year ($)*		Deduct: Fair Value as of Prior Fiscal Year End of Equity Awards Granted in Prior Fiscal Years that Failed to Meet Vesting Conditions in the Applicable Year ($)*		CAP ($)*
2025	PEO		2,540,204		(1,426,280)		1,842,580		737,485		—		16,562		—		3,710,551
2025	Average Non-PEO NEOs		1,229,606		(600,160)		597,227		62,906		115,830		(188,890)		(531,697)		684,822

Amount of equity award adjustments may differ from amount reported in the table above due to rounding. For purposes of the above adjustments, the fair value of equity awards on the applicable date were determined in accordance with ASC Topic 718, using valuation methodologies that are generally consistent with those used to determine the grant-date fair value for accounting purposes. The table below contains ranges of assumptions used in the valuation of outstanding equity awards for the relevant fiscal years. For more information, please see the notes to our financial statements in our Annual Report on Form 10-K and the footnotes to the Summary Compensation Table of this Proxy Statement.

Assumptions			As of the Measurement Dates in Fiscal Year 2025
Expected Term			4.10 – 9.00 years
Strike Price			$46.30 – $70.93
Volatility			82.13% – 86.05%
Dividend Yield			0.0% – 0.0%
Risk-Free Interest Rate			3.59% – 4.44%

(4)

For the relevant fiscal year, represents the cumulative total shareholder return (“TSR”) of our common stock at the end of each fiscal year. In each case, assumes reinvestment of dividends and an initial investment of $100 on December 31, 2020.

(5)

The dollar amounts reported represent the net loss reflected in the Company’s audited financial statements for the applicable year.

Narrative to Pay Versus Performance Table

Analysis of the Information Presented in the Pay Versus Performance Table

As described in more detail above in “Executive Compensation” in this Proxy Statement, the Company’s executive compensation program reflects a performance-driven compensation philosophy. While the Company utilizes several performance measures to align executive compensation with Company performance, those Company measures are not financial performance measures and are therefore not presented in the Pay Versus Performance table. Moreover, the Company generally seeks to incentivize long-term performance, and therefore does not specifically align the Company’s performance measures with CAP (as computed in accordance with Item 402(v) of Regulation S-K) for a particular year.

TABLE OF CONTENTS

Required Disclosure of the Relationship Between CAP and Financial Performance

In accordance with Item 402(v) of Regulation S-K, we are providing the following descriptions of the relationships between information presented in the Pay Versus Performance table above.

CAP and Net Income (Loss)

The graph below illustrates the relationship between our CAP and the Company’s financial performance over the five-year period shown in the tables above.

[MISSING IMAGE: bc_capvsnetloss-4clr.jpg]

CAP and Cumulative TSR

The graph below shows the relationship between the CAP to our PEO and the average CAP to our non-PEO NEOs, on the one hand, to the Company’s cumulative TSR over the five years presented in the table, on the other. In addition, the graph further illustrates the relationship between our TSR and that of the NASDAQ Biotechnology Index.

TABLE OF CONTENTS

All information provided above under the “Item 402(v) Pay Versus Performance” heading will not be deemed to be incorporated by reference into any filing of the Company under the Exchange Act, whether made before or after the date hereof and irrespective of any general incorporation language in any such filing, except to the extent the Company specifically incorporates such information by reference.

TABLE OF CONTENTS

NON-EMPLOYEE DIRECTOR COMPENSATION

The following table sets forth information regarding compensation earned by or paid to our non-employee directors for the fiscal year ended December 31, 2025:

Name	Fees Earned or Paid in Cash ($)(1)			Stock Awards ($)(2)(3)			Option Awards ($)(2)(3)			Total
Jean-Jacques Bienaimé		$	72,908		$	77,805		$	108,730		$	259,443
Nima Farzan			52,500			77,805			108,730			239,035
Carl L. Gordon(4)			46,000			77,805			108,730			232,535
Mary Ann Gray			61,000			77,805			108,730			247,535
Tomer Kariv(5)			39,538			79,223			21,016			139,777
Julius Knowles			52,500			77,805			108,730			239,035
Ran Nussbaum(6)			36,375			79,223			21,016			136,614
Alpna Seth			52,000			77,805			108,730			238,535
Charles Newton(7)			—			—			—			—

(1)

Amounts reported were paid under our non-employee director compensation policy, which was adopted effective as of the closing of our IPO, and amended and restated most recently on February 24, 2026.

(2)

Amounts reported represent (1) the aggregate grant date fair value of the RSU awards and stock options, as applicable, granted to our non-employee directors during 2025 under our 2020 Plan, computed in accordance with ASC Topic 718, excluding the effect of estimated forfeitures, and (2) the incremental fair value received by Mr. Kariv and Mr. Nussbaum with respect to the acceleration of the vesting of their stock options in connection with their resignations from our Board. The assumptions used in calculating the grant date fair value of the RSU awards and the stock options reported in this column are set forth in the notes to our audited financial statements included in our Annual Report on Form 10-K for the year ended December 31, 2025. These amounts do not reflect the actual economic value that will be realized by the non-employee directors upon vesting of the RSU awards or the stock options, the exercise of the stock options, or the sale of the common stock underlying such RSU awards and stock options.

(3)

The table below sets forth the aggregate number of outstanding RSU awards and shares underlying outstanding stock options held by each non-employee director as of December 31, 2025. None of our non-employee directors held other unvested stock awards as of December 31, 2025.

Name	Number of RSU Awards		Number of Shares Underlying Options
Jean-Jacques Bienaimé		5,250		28,100
Nima Farzan		5,250		55,586
Carl L. Gordon		5,250		47,086
Mary Ann Gray		5,250		63,673
Tomer Kariv(5)		—		—
Julius Knowles		5,250		47,086
Ran Nussbaum(6)		—		—
Alpna Seth		5,250		50,500
Charles Newton(7)		—		—

(4)

Dr. Gordon resigned from our Board and all committees thereof in March 2026.

(5)

Mr. Kariv resigned from our Board and all committees thereof in October 2025. In connection with Mr. Kariv’s resignation, our Board accelerated the vesting of the 10,500 stock options and 5,250 RSUs that Mr. Kariv received on June 4, 2025, effective as of October 14, 2025.

TABLE OF CONTENTS

(6)

Mr. Nussbaum resigned from our Board and all committees thereof in October 2025. In connection with Mr. Nussbaum’s resignation, our Board accelerated the vesting of the 10,500 stock options and 5,250 RSUs that Mr. Nussbaum received on June 4, 2025, effective as of October 14, 2025.

(7)

Mr. Newton was appointed to the Board, effective March 9, 2026.

Dr. Seehra, our Chief Executive Officer, is also a member of our Board but does not receive any additional compensation for his service as a director. See the section titled “Executive Compensation” for more information regarding the compensation earned by Dr. Seehra for his service as our Chief Executive Officer.

Non-Employee Director Compensation Policy

Our Board maintains a non-employee director compensation policy, pursuant to which each of our directors who is not an employee or consultant of our Company is eligible to receive compensation for service on our Board and committees of our Board. In March 2020, following analysis of market research and advice from its compensation consultant, our Board adopted the non-employee director compensation policy, which became effective on April 7, 2020. Following review of market research and advice from its compensation consultant, our Board amended our non-employee director compensation policy, effective on February 16, 2023 and most recently, effective February 24, 2026.

Cash Compensation

Under the non-employee director compensation policy, we pay each of our non-employee directors a cash retainer for service on our Board and committees of our Board. These retainers will be payable in arrears in four equal quarterly installments on the last day of each fiscal quarter in which the service occurred, provided that the amount of such payment will be prorated for any portion of such quarter that the director is not serving on our Board.

Non-employee directors are eligible to receive cash compensation as follows:

	Annual Cash Retainer ($)
Annual retainer		41,500
Additional retainer for Chair		33,000
Additional retainer for Lead Independent Director		31,000
Additional retainer for Audit Committee Chair		17,000
Additional retainer for Audit Committee member		8,500
Additional retainer for Compensation Committee Chair		14,000
Additional retainer for Compensation Committee member		7,000
Additional retainer for Nominating and Corporate Governance Committee Chair		10,000
Additional retainer for Nominating and Corporate Governance Committee member		5,000

Equity Compensation

In addition to cash compensation, each non-employee director will be eligible to receive RSUs and options. Any RSUs and options granted under the non-employee director compensation policy will have a term of ten years from the date of grant, subject to earlier termination in connection with a termination of service. Vesting schedules for equity awards will be subject to the non-employee director’s continuous service on each applicable vesting date, provided that each such award will vest in full upon a change in control of the Company.

Upon the termination of service of the non-employee director for any reason other than death, disability or cause, his or her equity awards granted under the non-employee director compensation policy shall remain exercisable for 12 months following his or her date of termination.

TABLE OF CONTENTS

Initial Award

Each new non-employee director elected or appointed to our Board will be granted (i) an initial, one-time stock option to purchase a number of shares of our common stock having a grant date fair value, as determined in accordance with ASC Topic 718, equal to $150,000 (the “Initial Option Grant”); provided, that the number of shares of common stock subject to the Initial Option Grant will not exceed 0.075% of the number of shares of our common stock outstanding as of the applicable grant date; and (ii) an RSU award covering a number of shares of our common stock having a grant date fair value, as determined in accordance with ASC Topic 718, equal to $150,000 (the “Initial RSU Grant”); provided, that the number of shares of common stock subject to the Initial RSU Grant will not exceed 0.075% of the number of shares of our common stock outstanding as of the applicable grant date. The shares subject to each Initial Option Grant will vest in equal quarterly installments such that the option is fully vested on the third anniversary of the grant date, subject to such non-employee director’s continued service through each such vesting date. The Initial RSU Grant will vest in equal quarterly installments on each Quarterly Vesting Date (as defined below) over a three-year period, subject to such non-employee director’s continued service through each such vesting date “Quarterly Vesting Date” means the 15th of each of February, May, August and November.

Annual Awards

On the date of each annual meeting of stockholders of our Company, each non-employee director that continues to serve as a non-employee member of the Board following such stockholder meeting (other than a director receiving an Initial Option Grant and an Initial RSU Grant less than three months prior to such stockholder meeting) will be automatically, and without further action by the Board or the Compensation Committee of the Board, granted (i) a stock option to purchase a number of shares of our common stock having a grant date fair value, as determined in accordance with ASC 718, equal to $75,000 (the “Annual Option Grant”); provided, that the number of shares of common stock subject to the Annual Option Grant will not exceed 0.0375% of the number of shares of our common stock outstanding as of the applicable grant date; and (ii) an RSU award covering a number of shares of common stock having a grant date fair value, as determined in accordance with ASC 718, equal to $75,000 (the “Annual RSU Grant”); provided, that the number of shares of common stock subject to the Annual RSU Grant will not exceed 0.0375% of the number of shares of our common stock outstanding as of the applicable grant date. The shares subject to the Annual Option Grant will vest in equal quarterly installments over the 12 months following the grant date, provided that the Annual Option Grant will in any case be fully vested on the date of our next annual stockholder meeting, subject to the non-employee director’s continued service through such vesting date. The Annual RSU Grant will fully vest on the earlier of (A) the first anniversary of the grant date and (B) the date of our next annual stockholder meeting, subject to the non-employee director’s continued service through such vesting date.

TABLE OF CONTENTS

EQUITY COMPENSATION PLAN INFORMATION

The following table summarizes our equity compensation plan information as of December 31, 2025. Information is included for equity compensation plans approved by our stockholders. We do not have any equity compensation plans not approved by our stockholders:

Plan Category	(a) Number of Securities to be Issued Upon Exercise of Outstanding Options, Warrants And Rights		(b) Weighted-Average Exercise Price of Outstanding Options, Warrants and Rights			(c) Number of Securities Remaining Available for Issuance Under Equity Compensation Plans (Excluding Securities Reflected in Column (a))
Equity compensation plans approved by security holders:
2017 Stock Incentive Plan, as amended		412,099		$	0.35		—(1)
2020 Equity Incentive Plan		4,206,457(2)		$	43.02(3)		3,146,054(4)
2020 Employee Stock Purchase Plan		—			—		1,641,602(5)
Equity compensation plans not approved by security holders		—			—		—
Total		4,618,556					4,787,656

(1)

No further grants were made under our 2017 Stock Incentive Plan, as amended, after the completion of our IPO on April 13, 2020.

(2)

Consists of (i) 3,364,607 shares to be issued upon exercise of outstanding options under the 2020 Plan as of December 31, 2025, (ii) 125,000 shares to be issued upon exercise of outstanding performance-based options under the 2020 Plan as of December 31, 2025, (iii) 626,350 shares to be issued upon vesting of outstanding RSU awards under the 2020 Plan as of December 31, 2025, and (iv) 90,500 shares to be issued upon vesting of outstanding performance-based RSU awards under the 2020 Plan as of December 31, 2025.

(3)

Consists of the weighted average exercise price of the 3,489,607 stock options outstanding on December 31, 2025. The calculation of the weighted average exercise price does not include outstanding equity awards that are received or exercised for no consideration.

(4)

The number of shares of common stock reserved for issuance under the 2020 Plan will automatically increase on January 1 of each year, beginning on January 1, 2021 and continuing through and including January 1, 2030, by 4.0% of the total number of shares of our common stock outstanding on December 31 of the preceding calendar year, or a lesser number of shares determined by our Board. Pursuant to the terms of the 2020 Plan, an additional 781,748 shares were added to the number of available shares effective January 1, 2026.

(5)

The number of shares of common stock reserved for issuance under the 2020 Employee Stock Purchase Plan will automatically increase on January 1 of each year, beginning on January 1, 2021 and continuing through and including January 1, 2030, by the lesser of (i) 1% of the total number of shares of our common stock outstanding on December 31 of the preceding calendar year, (ii) 455,852 shares or (iii) such lesser number of shares determined by our Board. Pursuant to the terms of the 2020 Employee Stock Purchase Plan, an additional 195,437 shares were added to the number of available shares effective January 1, 2026.

TABLE OF CONTENTS

TRANSACTIONS WITH RELATED PERSONS AND INDEMNIFICATION

The following is a summary of transactions since January 1, 2025, to which we have been a participant in which the amount involved exceeded or will exceed $120,000 and in which any of our directors, executive officers or holders of more than 5% of any class of our capital stock at the time of such transaction, or any members of their immediate family, had or will have a direct or indirect material interest.

Investors’ Rights, Voting and Stockholders Agreements

In connection with our convertible preferred stock financings, we entered into investors’ rights, voting and stockholder agreements containing registration rights, information rights, voting rights and rights of first refusal, among other things, with certain holders of our convertible preferred stock and certain holders of our common stock including the Pontifax Parties, the OrbiMed Entities, Partners Innovation Fund, LLC and Partners Innovation Fund II, L.P. These stockholder agreements terminated upon the closing of our IPO in April 2020, except for the registration rights granted under our amended and restated investors’ rights agreement, which terminated in April 2025.

Employment Arrangements

We have entered into employment agreements with certain of our executive officers. For more information regarding these agreements with our NEOs, see “Executive Compensation.”

Executive and Director Compensation

We have granted stock options to certain of our executive officers and directors. For more information regarding the stock options granted to our directors and NEOs, see “Executive Compensation” and “Non-Employee Director Compensation.”

Letter Agreement

On April 17, 2025, we entered into a letter agreement with Pontifax Venture Capital (together with its affiliates, the “Pontifax Parties”), a holder of more than 5% of our common stock outstanding at the time of the transaction, regarding the membership and composition of our Board (the “Letter Agreement”). Pursuant to the Letter Agreement, we appointed Mr. Nussbaum to our Board. The Letter Agreement also contained customary standstill and mutual non-disparagement provisions and remains in effect until the earlier of (i) December 31, 2025 and (ii) the 30th day prior to the notice deadline under our bylaws (as in effect on the date of the Letter Agreement) for the nomination of director candidates by a stockholder for election to the Board at our 2026 Annual Meeting of Stockholders. The Letter Agreement was terminated in October 2025.

October 2025 Share Repurchases

On October 15, 2025, we entered into stock purchase agreements with certain entities affiliated with ADAR1 Capital Management (collectively the “ADAR1 Parties,” and such stock purchase agreement, the “ADAR1 Repurchase Agreement”), a holder of more than 5% of our common stock outstanding at the time of the transaction, and the Pontifax Parties, and such stock purchase agreement, the “Pontifax Repurchase Agreement” and, together with the ADAR1 Repurchase Agreement, the “Repurchase Agreements”). Pursuant to the terms and conditions of the Repurchase Agreements, the ADAR1 Parties and the Pontifax Parties sold all of the shares of common stock beneficially owned by them, being an aggregate of 10,176,595 shares of common stock, to us at a per share purchase price of $17.75 per share, for an aggregate purchase price of $180.6 million. In addition, concurrently with the execution of the Pontifax Repurchase Agreement, each of Tomer Kariv and Ran Nussbaum resigned from our board of directors and all committees thereof.

Pursuant to the Repurchase Agreements, each of the ADAR1 Parties and the Pontifax Parties agreed to customary standstill restrictions and voting commitments, which will remain in effect until immediately following the final certification of the voting results for our 2028 annual stockholder meeting. We and each of the ADAR1 Parties and the Pontifax Parties also agreed to customary mutual non-disparagement obligations to remain in effect during the same period.

TABLE OF CONTENTS

November 2025 Issuer Tender Offer

On October 20, 2025, we announced that our Board authorized a tender offer to repurchase shares of our common stock (the “Tender Offer”), which we launched on October 20, 2025 and completed on November 21, 2025. On November 20, 2025, we disclosed that a total of 17,712,262 shares of our common stock were validly tendered and not validly withdrawn. In accordance with the terms and conditions of the Tender Offer, we accepted for purchase a total of 10,950,165 shares of our common stock at a purchase price of $17.75 per share, for an aggregate purchase price of approximately $194.4 million.

In connection with the Tender Offer, we repurchased (i) 140,057 shares of our common stock from OrbiMed Private Investments VII, LP (“OPI VII”) and (ii) 74,465 shares of our common stock from OrbiMed Genesis Master Fund, L.P. (“Genesis”). OPI VII and Genesis are collectively referred to as the “OrbiMed Entities.” OrbiMed Capital GP VII LLC (“OrbiMed GP”) is the general partner of OPI VII and OrbiMed Advisors LLC (“OrbiMed Advisors”) is the managing member of OrbiMed GP. By virtue of such relationships, OrbiMed GP and OrbiMed Advisors may be deemed to have voting power and investment power over the securities held by OPI VII and as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Genesis GP LLC (“Genesis GP”) is the general partner of Genesis and OrbiMed Advisors is the managing member of Genesis GP. By virtue of such relationships, Genesis GP and OrbiMed Advisors may be deemed to have voting power and investment power over the securities held by Genesis and as a result, may be deemed to have beneficial ownership over such securities. Dr. Gordon, who was a member of our Board at the time of the Tender Offer, is a managing partner of OrbiMed Advisors and, as a result, may be deemed to share voting and investment power with respect to the shares held by each of the OrbiMed Entities.

Additionally, in connection with the Tender Offer, we repurchased (i) 191,527 shares of our common stock from Partners Innovation Fund, LLC (“PIF I”) and (ii) 130,494 shares of our common stock from Partners Innovation Fund II, L.P. (“PIF II”). PIF I and PIF II are collectively referred to as the “Partners Entities.” Partners Innovation Fund, LLC (“Partners GP I”) is the ultimate general partner of PIF I, and Partners Innovation Fund II, LLC (“Partners GP II”) is the ultimate general partner of PIF II. Julius Knowles, a member of our Board, is a partner of each of Partners GP I and Partners GP II, and, as a result, may be deemed to share voting and investment power with respect to the shares held by each of the Partners Entities.

Indemnification Agreements

We provide indemnification for our directors and executive officers so that they will be free from undue concern about personal liability in connection with their service to the Company. Under our bylaws, we are required to indemnify our directors and executive officers to the extent not prohibited under Delaware or other applicable law. We have also entered into indemnity agreements with certain officers and directors. These agreements provide, among other things, that we will indemnify the officer or director, under the circumstances and to the extent provided for in the agreement, for expenses, damages, judgments, fines and settlements he or she may be required to pay in actions or proceedings which he or she is or may be made a party by reason of his or her position as a director, officer or other agent of the Company, and otherwise to the fullest extent permitted under Delaware law and our bylaws.

Related Party Transaction Policy

We maintain a related party transaction policy that sets forth our procedures for the identification, review, consideration and approval or ratification of related party transactions. The policy became effective on April 7, 2020. For purposes of our policy only, a related party transaction is a transaction, arrangement or relationship, or any series of similar transactions, arrangements or relationships, in which we and any related party are, were or will be participants and in which the amount involved exceeds the lesser of $120,000 and one percent of the average of our total assets at year-end for the last two completed fiscal years. Transactions involving compensation for services provided to us as an employee or director are not covered by this policy. A related party is any executive officer, director or beneficial owner of more than 5% of any class of our voting securities, including any of their immediate family members and any entity owned or controlled by such persons.

TABLE OF CONTENTS

Under the policy, if a transaction has been identified as a related party transaction, including any transaction that was not a related party transaction when originally consummated or any transaction that was not initially identified as a related party transaction prior to consummation, our management must present information regarding the related party transaction to our Audit Committee, or, if Audit Committee approval would be inappropriate, to another independent body of our Board, for review, consideration and approval or ratification. The presentation must include a description of, among other things, the material facts, the interests, direct and indirect, of the related parties, the benefits to us of the transaction and whether the transaction is on terms that are comparable to the terms available to or from, as the case may be, an unrelated third party or to or from employees generally. Under the policy, we will collect information that we deem reasonably necessary from each director, executive officer and, to the extent feasible, significant stockholder to enable us to identify any existing or potential related-person transactions and to effectuate the terms of the policy.

In addition, under our Code of Business Conduct and Ethics, our employees and directors have an affirmative responsibility to disclose any transaction or relationship that reasonably could be expected to give rise to a conflict of interest.

In considering related party transactions, our Audit Committee, or other independent body of our Board, will take into account the relevant available facts and circumstances including, but not limited to:

•

the risks, costs and benefits to us;

•

the impact on a director’s independence in the event that the related party is a director, immediate family member of a director or an entity with which a director is affiliated;

•

the availability of other sources for comparable services or products; and

•

the terms available to or from, as the case may be, unrelated third parties or to or from employees generally.

The policy requires that, in determining whether to approve, ratify or reject a related party transaction, our Audit Committee, or other independent body of our Board, must consider, in light of known circumstances, whether the transaction is in, or is not inconsistent with, our best interests and those of our stockholders, as our Audit Committee, or other independent body of our Board, determines in the good faith exercise of its discretion.

TABLE OF CONTENTS

DELINQUENT SECTION 16(a) REPORTS

Section 16(a) of the Exchange Act requires the Company’s directors and executive officers, and persons who own more than 10% of a registered class of the Company’s equity securities, to file with the SEC initial reports of ownership and reports of changes in ownership of common stock and other equity securities of the Company. Such officers, directors and greater than 10% stockholders are required by SEC regulations to furnish the Company with copies of all Section 16(a) forms they file.

To the Company’s knowledge, based solely on a review of the copies of such reports furnished to the Company and written representations that no other reports were required, during the year ended December 31, 2025, we believe that all of our officers, directors and greater than 10% beneficial owners timely filed all reports required by Section 16(a) of the Exchange Act, except for (i) Julius Knowles, who filed a Form 4 to report a disposition of common stock by the Partners Entities in connection with the Tender Offer on December 18, 2025, which was due on November 25, 2025, and (ii) Carl Gordon, who filed a Form 4 to report a disposition of common stock by the OrbiMed Entities in connection with the Tender Offer on December 18, 2025, which was due on November 25, 2025.

TABLE OF CONTENTS

HOUSEHOLDING OF PROXY MATERIALS

The SEC has adopted rules that permit companies and intermediaries (e.g., brokers) to satisfy the delivery requirements for Notices of Internet Availability of Proxy Materials or other Annual Meeting materials with respect to two or more stockholders sharing the same address by delivering a single Notice of Internet Availability of Proxy Materials or other Annual Meeting materials addressed to those stockholders. This process, which is commonly referred to as “householding,” potentially means extra convenience for stockholders and cost savings for companies.

This year, a number of brokers with account holders who are our stockholders will be “householding” our proxy materials. A single Notice of Internet Availability of Proxy Materials will be delivered to multiple stockholders sharing an address unless contrary instructions have been received from the affected stockholders. Once you have received notice from your broker that they will be “householding” communications to your address, “householding” will continue until you are notified otherwise or until you revoke your consent. If, at any time, you no longer wish to participate in “householding” and would prefer to receive a separate Notice of Internet Availability of Proxy Materials, please notify your broker or us. Direct your written request to Keros Therapeutics, Inc., 1050 Waltham Street, Suite 302, Lexington, Massachusetts 02421, Attention: Corporate Secretary. Stockholders who currently receive multiple copies of the Notices of Internet Availability of Proxy Materials at their addresses and would like to request “householding” of their communications should contact their brokers.

TABLE OF CONTENTS

OTHER MATTERS

The Board of Directors knows of no other matters that will be presented for consideration at the Annual Meeting. If any other matters are properly brought before the Annual Meeting, it is the intention of the persons named in the accompanying proxy to vote on such matters in accordance with their best judgment.

				By Order of the Board of Directors

				Esther Cho Corporate Secretary April 22, 2026

A copy of our Annual Report on Form 10-K for the fiscal year ended December 31, 2025, as filed with the Securities and Exchange Commission, is available without charge upon written request to: Keros Therapeutics, Inc., 1050 Waltham Street, Suite 302, Lexington, Massachusetts 02421, Attention: Corporate Secretary.

TABLE OF CONTENTS

[MISSING IMAGE: px_26kerostherapg01-bw.jpg]

As a stockholder of Keros Therapeutics, Inc., you have the option of voting your shares electronically through the Internet or by telephone, eliminating the need to return the proxy card. Your electronic or telephonic vote authorizes the named proxies to vote your shares in the same manner as if you marked, signed, dated, and returned the proxy card. Votes submitted electronically over the Internet or by telephone must be received by 11:59 p.m., ET, on June 2, 2026.KEROS THERAPEUTICS, INC.ANNUAL MEETING OF STOCKHOLDERS JUNE 3, 2026 AT 11:00 A.M. ETTHIS PROXY IS SOLICITED ON BEHALF OF THE BOARD OF DIRECTORS OF KEROS THERAPEUTICS, INC.The undersigned hereby appoints Jasbir Seehra and Keith Regnante (the “Named Proxies”), and each or either of them, as the true and lawful attorneys of the undersigned, with full power of substitution and revocation, and hereby authorizes them, and each of them, to represent and to vote, as designated on the reverse side of this ballot, all of the shares of common stock of Keros Therapeutics, Inc. (the “Company”) that the undersigned is entitled to vote at the Annual Meeting of Stockholders (the “Annual Meeting”) to be held at 11:00 AM Eastern Time on June 3, 2026 and any adjournment or postponement thereof, conferring authority upon such true and lawful attorneys to vote in their discretion on such other matters as may properly come before the meeting and revoking any proxy heretofore given.The Annual Meeting will be held virtually. In order to attend the Annual Meeting, you must register at https://web.viewproxy.com/keros/2026 by 11:59 PM Eastern Time on June 2, 2026. On the day of the Annual Meeting, if you have properly registered, you may enter the Annual Meeting by clicking on the link you received via email in your registration confirmations. Further instructions on how to attend and vote during the Annual Meeting are contained in the Proxy Statement in the sections titled “Questions and Answers About These Proxy Materials and Voting – How do I attend the Annual Meeting?” and “Questions and Answers About These Proxy Materials and Voting – How can I vote?”

TABLE OF CONTENTS

[MISSING IMAGE: px_26kerostherapg02-bw.jpg]

Important Notice Regarding the Availability of Proxy Materials for the Annual Meeting of Stockholders to be held on June 3, 2026 at 11:00 A.M. ET:The Notice, Proxy Statement and Annual report are available at:https://web.viewproxy.com/keros/2026☒When properly executed, your proxy card/voting instruction form will be voted in the manner you direct. If you do not specify your choices, your shares will be voted FOR all the nominees listed in Proposal 1 and FOR Proposals 2 and 3.

DEF 14A 0001664710 false 0001664710 2025-01-01 2025-12-31 0001664710 2024-01-01 2024-12-31 0001664710 2023-01-01 2023-12-31 0001664710 ecd:EqtyAwrdsInSummryCompstnTblForAplblYrMember ecd:PeoMember 2025-01-01 2025-12-31 0001664710 ecd:YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember ecd:PeoMember 2025-01-01 2025-12-31 0001664710 ecd:ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember ecd:PeoMember 2025-01-01 2025-12-31 0001664710 ecd:VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember ecd:PeoMember 2025-01-01 2025-12-31 0001664710 ecd:ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember ecd:PeoMember 2025-01-01 2025-12-31 0001664710 ecd:FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember ecd:PeoMember 2025-01-01 2025-12-31 0001664710 ecd:EqtyAwrdsInSummryCompstnTblForAplblYrMember ecd:NonPeoNeoMember 2025-01-01 2025-12-31 0001664710 ecd:YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember ecd:NonPeoNeoMember 2025-01-01 2025-12-31 0001664710 ecd:ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember ecd:NonPeoNeoMember 2025-01-01 2025-12-31 0001664710 ecd:VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember ecd:NonPeoNeoMember 2025-01-01 2025-12-31 0001664710 ecd:ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember ecd:NonPeoNeoMember 2025-01-01 2025-12-31 0001664710 ecd:FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember ecd:NonPeoNeoMember 2025-01-01 2025-12-31 iso4217:USD iso4217:USD xbrli:shares xbrli:pure

Source: View Original Filing on SEC EDGAR

FAQ

When is the 2026 Keros Therapeutics (KROS) annual stockholder meeting and how will it be held?

The 2026 annual meeting is scheduled for June 3, 2026 at 11:00 a.m. Eastern time. It will be conducted in a virtual-only format via live audio webcast, with advance registration required through the specified meeting website for stockholders wishing to attend and vote.

What key proposals are Keros Therapeutics (KROS) stockholders voting on at the 2026 annual meeting?

Stockholders will vote on electing two Class III directors, ratifying Deloitte & Touche LLP as independent auditor for the year ending December 31, 2026, and approving, on an advisory basis, the compensation of named executive officers, often called a say-on-pay vote under U.S. securities rules.

What strategic changes did Keros Therapeutics (KROS) make to its pipeline in 2025?

In 2025, Keros decided to exclusively prioritize clinical advancement of rinvatercept, its lead product candidate, believed to help Duchenne muscular dystrophy. It discontinued all material internal development activities for cibotercept after previously terminating its pulmonary arterial hypertension program following review of TROPOS Phase 2 safety and efficacy data.

How is Keros Therapeutics (KROS) advancing rinvatercept in neuromuscular diseases?

Keros reports positive Phase 1 results for rinvatercept, achieving key safety and pharmacologic objectives. It is progressing toward a Phase 2 trial in Duchenne muscular dystrophy and collaborating with Massachusetts General Hospital on a planned Phase 2 ALS trial within the Healey ALS MyMatch program, with regulatory engagement expected in the second half of 2026.

What capital return actions did Keros Therapeutics (KROS) complete for stockholders?

Following a review of strategic alternatives, Keros’ board authorized a $375 million capital return program. The company completed this through share repurchases, including a tender offer that concluded in November 2025, aiming to deliver immediate value while retaining financial flexibility to progress its clinical pipeline.

How many Keros Therapeutics (KROS) shares are entitled to vote at the 2026 meeting and what constitutes a quorum?

As of the April 6, 2026 record date, 19,787,837 common shares were outstanding and entitled to vote. A quorum for the annual meeting requires stockholders representing at least 9,893,919 shares to be present virtually or represented by proxy so official business can proceed.

Keros Therapeutics (NASDAQ: KROS) focuses on rinvatercept and completes $375M capital return

Rhea-AI Filing Summary

Positive

Negative

Insights

Key Figures

Key Terms

Compensation Summary

FAQ

When is the 2026 Keros Therapeutics (KROS) annual stockholder meeting and how will it be held?

What key proposals are Keros Therapeutics (KROS) stockholders voting on at the 2026 annual meeting?

What strategic changes did Keros Therapeutics (KROS) make to its pipeline in 2025?

How is Keros Therapeutics (KROS) advancing rinvatercept in neuromuscular diseases?

What capital return actions did Keros Therapeutics (KROS) complete for stockholders?

How many Keros Therapeutics (KROS) shares are entitled to vote at the 2026 meeting and what constitutes a quorum?

Keros Therapeutics (NASDAQ: KROS) focuses on rinvatercept and completes $375M capital return

Rhea-AI Filing Summary

Positive

Negative

Insights

Biotech & governance analyst neutral

Key Figures

Key Terms

Compensation Summary

FAQ

When is the 2026 Keros Therapeutics (KROS) annual stockholder meeting and how will it be held?

What key proposals are Keros Therapeutics (KROS) stockholders voting on at the 2026 annual meeting?

What strategic changes did Keros Therapeutics (KROS) make to its pipeline in 2025?

How is Keros Therapeutics (KROS) advancing rinvatercept in neuromuscular diseases?

What capital return actions did Keros Therapeutics (KROS) complete for stockholders?

How many Keros Therapeutics (KROS) shares are entitled to vote at the 2026 meeting and what constitutes a quorum?